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Abstract 
Role of Nicotinic Acetylcholine Receptors in Experimental Colitis 
                                      By Shakir Dakheelallah Zayed AlSharari, B.S.Pharm 
A Dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of 
Philosophy at Virginia Commonwealth University, 2012 
 
Major Director: Dr. M. Imad Damaj 
Professor, Pharmacology and Toxicology 
 
      Substantial evidence in the literature shows that tobacco smoking has complex and divergent 
effects on inflammatory bowel diseases (IBD). It ameliorates ulcerative colitis (UC); whereas it 
aggravates the risk of Crohn’s disease (CD) and affects the disease course and severity. Studies 
have shown that nicotine has a positive influence on symptoms of UC. Also, it is demonstrated 
that nicotinic acetylcholine receptor, especially α7 subunit plays an essential component in the 
vagus nerve-based cholinergic anti-inflammatory effects. In the present study, we explored the 
effect of nicotine and α7 nicotinic agonists treatment in the DSS colitis mouse model. We also 
investigated the effects of cotinine, a major metabolite of nicotine, in the model. Methods: 
Different groups of C57BL6 mice, as well as α7, α5, and β2 nicotinic receptor knock out mice, 
and their littermates wild-type nicotinic receptor male adult mice were given DSS solution freely 
in the drinking water for 7 consecutive days after which tap water was given on the 8th day. We 
measured a Disease Activity Index (DAI) that includes body weight loss, blood presence in 
stools, stool consistency, local rectal irritation and length of the colon. The mice were then 
sacrificed on day 8 to allow examination of the entire colon. Disease severity and colon tissue 
histology and inflammatory markers including colonic myeloperoxidase (MPO) and colonic 
tumor necrosis factor-α (TNF-α) were evaluated. Levels of MPO and TNF-α were determined by 
enzyme-linked immunosorbent assay analysis of the homogenized colon samples. The effect of 
oral, subcutaneous, mini pump nicotine, and oral cotinine treatments were examined on 
xvi 
experimental colitis induced by 2.5% DSS in mice. In addition, we measured the plasma levels 
of the nicotine and cotinine in our treatment protocols. Results: The DSS 2.5% model of colitis 
is easily induced in mice. Administration of low doses of oral nicotine (12.5 and 25 µg/ml), but 
not high doses in DSS-treated mice displayed a significant decrease in disease activity index 
value, total histological damage scores, as well as colonic level of TNF-α compared to the 
control group. However, the anti-inflammatory effect of nicotine was not seen with chronic s.c., 
mini pump nicotine or oral cotinine administration. Differences in plasma levels of nicotine and 
cotinine do not seem to account for this lack of effect. Moreover, neither nicotine nor cotinine 
reversed colon length shortening in DSS-treated mice, except with the 0.5 mg/kg s.c. dose of 
nicotine. There was no change in MPO activity among the groups treated with oral or s.c. 
nicotine. Cotinine oral administration on its own failed to show a significant effect in the DSS 
model of colitis. α7 KO mice displayed a significantly increased in DAI value starting from day 
4 till day 8, histological damage scores and TNF-α levels of were increased significantly 
compared to their littermate WT mice. Moreover, pretreatments with PHA-543613 (8 mg/kg), a 
selective α7 agonist, and choline chloride (40 ug/ml), an α7 nAChR natural agonist, significantly 
reduced clinical parameters in DSS-treated mice; however, they slightly inhibited the increase in 
the colonic TNF-α levels compare with vehicle DSS-treated mice. Moreover, PNU-120596 (3 
mg/kg), a positive allosteric modulator for α7 nAChRs, significantly reduced DAI value and total 
histological damage score in DSS-treated mice. Conclusion: Results obtained from this study 
highlight that dose and route of administration play a critical role in the protective effect of 
nicotine in the DSS mouse colitis model. Also, these data suggest that α7 nAChR has a 
protective role in colitis with narrower therapeutic index. Data obtained from this study further 
xvii 
understanding of the effect of nicotine in UC and may contribute in the development of new 
pharmaceutical designs for targeting nAChRs for the treatment of ulcerative colitis.  
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1 
                                                               CHAPTER ONE 
General Introduction  
1.1. Ulcerative Colitis: definition, clinical presentation, and diagnosis 
Ulcerative colitis (UC) is one of the main two entities of inflammatory bowel diseases (IBD), 
beside Crohn’s disease (CD). Differences between these two typical IBD disorders are related to 
the disease nature and location as a result of abnormal immune response, various genetic and 
environmental factors (Baumgart and Carding, 2007; Strober et al., 2007). Interestingly, cigarette 
smoking has a dual opposite influence on these two diseases; it exacerbates CD, but ameliorates 
the course of UC disease (Tobin et al., 1987). For that reason, in my dissertation, I pay special 
attention to UC. I also discuss the influence of nicotine and the involvement of nicotinic receptor 
subtypes in UC. Ulcerative colitis is a chronic inflammatory disease with recurrent symptoms 
and significant morbidity of unknown etiology, due partly to genetic susceptibility to 
environmental factors that misdirect the mucosal immune system response to attack the epithelial 
layer of the colon causing inflammation and was first described by Sir Wilks (Wilks S, 1859). 
UC is characterized by inflammation of the mucosa and occasionally the submucosa of the colon 
and it is the most common form of inflammatory bowel disease worldwide that results in 
excessive mononuclear cell and neutrophil infiltration into mucosa and submucosa vicinities that 
affects primarily the distal colon and rectum (Hanauer, 1996). The incidence of UC in North 
America ranges from 2.2 to 14.3 cases per 100,000 (Loftus, 2004) and the adult prevalence of 
UC in the United States has ranged between 37 and 238 per 100,000 (Loftus, 2004; Kappelman 
et al., 2007) with age range between 15 and 30 years. Northern Europe and North America 
populations have the highest incidence and prevalence of IBD (Ahuja and Tandon, 2010). 
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1.2.  Abnormalities in Immune Responses in Ulcerative Colitis  
    UC is associated with alterations of innate or adaptive arms of the immune response. The 
increased levels of IgM, IgA, and IgG are common in IBD, with an increase in IgG1 antibodies 
in UC (Takahashi and Das, 1985). In addition, cytokines are up-regulated at the mucosa of 
patients with UC, and play central components of the inflammatory pathways in ulcerative colitis. 
Abnormalities of adaptive immunity in the UC are defined by mucosal CD4+ lymphocytes, the T 
helper 1 (Th1) and T helper type 2 cells (Th2) paradigm. Immune responses have been classified 
based on the prominent cytokine profile in different disease conditions. Although this traditional 
concept of mucosal immunology considered ulcerative colitis mainly as a Th2-mediated 
response, due to the lack of IFN γ expression increase rather than IL-4 elevation (Fuss et al., 
1996), recent research focuses on the alternative Th2 responses such as role of IL-13 in UC. This 
approach indicates that there is a significant increase of IL-13 (Fuss et al., 2004, Heller et al., 
2005). It has been reported that both of IL-13 receptors, IL-4Rα and IL-13Rα2, were expressed 
in intestinal epithelial cells and that IL-13 has an important role on epithelial barrier function 
(Heller et al., 2005) which indicates the involvement of IL-13 in UC signaling pathogenesis 
(Fuss and Strober, 2008). It has been proposed that colonocytes are the main players in the UC 
pathogenesis since the inflammation in UC does not reach into the small intestine (for review see, 
Danese and Fiocchi, 2011). The defects in UC epithelial include impaired epithelial barrier and 
reduced peroxisome proliferator activated receptor γ (PPAR-γ) expression (Dubuquoy et al., 
2003). In fact, PPARγ ligands treatment has been reported to reduce colonic inflammation in 
animal colitis models (Su et al., 1999; Dubuquoy et al., 2006) and reduce the pro-inflammatory 
cytokine including IL-1β and TNF-α (Dubuquoy et al., 2006).  
3 
Clinical Presentations. The diagnosis of colitis is generally established by assessment of 
inflammatory markers followed by colonoscopy, with biopsy of pathological lesions to 
determine specific histologic characteristics. The hallmark symptoms of UC are intermittent 
bloody diarrhea, rectal urgency, and tenesmus (straining at stool) (Kornbluth and Sachar, 2004). 
The ultimate diagnosis relies on a combination of history, endoscopic finding, histologic features.   
Patients typically present with bloody diarrhea and passage of pus and/or mucus that often 
persists for months and is accompanied by abdominal cramping during bowel movements. In 
mild ulcerative colitis, rectal mucosal inflammation (proctitis) is sometimes associated with fecal 
urgency and the presence of blood. In moderate disease, small erosions are present, however, in 
severe UC, ulcerations with bleeding are seen.  
Histological Features. UC is not a static disease but is a disease that frequently changes as a 
result of active stage and remissions. In UC, inflammation is characteristically limited to the 
mucosal layer, with inflammatory cell infiltrates into lamina propria. Infiltrates consist primarily 
of lymphocytes, plasma cells, and granulocytes; neutrophils can invade crypt epithelium causing 
cryptitis and accumulate resulting in crypt abscesses (Loddenkemper, 2009). Other histological 
features include depletion of goblet cells, alteration of shapes and sizes of crypts, and colonic 
ulcerations.  
1.3. Conventional Pharmacological Therapy 
  Management of ulcerative colitis involves acute treatment of all inflammatory symptoms, 
followed by maintenance of remission. Treatment of UC, generally depends on the disease 
severity (mild, moderate, or severe) (Stange et al., 2008; Travis et al., 2008; Kornbluth and 
Sachar, 2010), and most commonly requires sulfasalazine and 5-aminosalicylates given orally or 
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rectally (either suppository or enema), representing first-line therapy for UC, with approximate 
50% remission rate (Nielsen and Munck, 2007).  Many UC patients receive sub doses of drugs 
(mainly the aminosalicylates), continue to take glucocorticoids as a maintenance therapy, or may 
require biologic agents, such as immunosuppressive therapy, azathioprine, 6-mercaptopurine, or 
cyclosporine to control the symptoms. However, 5-aminosalicylic acid drugs and glucocorticoids 
have poor efficacy and frequency of adverse effects such as nausea, vomiting, fever, headache, 
and gastrointestinal distress for 5-ASA with the frequency rate of these adverse events between 
20-30% and a 5-10% withdrawal rate (Moss and Peppercorn, 2007) and for steroids these side 
effects include weight gain, fluid retention, immune suppression, hypokalemia, hypertension 
(Ardizzone and Bianchi Porro, 2002) that limit their use (Rosenberg and Peppercorn, 2010).  It is, 
therefore, highly desirable to develop more efficacious treatments that elicit fewer side events 
than presently used medications.  Alternative medicine treatments include probiotics, nicotine 
patches and fish oil. In some severe cases, colectomy is a final option.  
1.4.  Cigarette Smoking and Ulcerative Colitis disease 
      UC has been linked to tobacco smoking for more than three decades. Smoking cigarettes is 
associated with less frequent exacerbations of ulcerative colitis (Cosnes, 2004). Moreover, 
tobacco smoking has been reported to often have a beneficial outcome on the course of activity 
of UC in smokers (Boyko et al., 1988; Mokbel et al., 1998; Gheorghe et al, 2004; Höie et al., 
2007) and associated with fewer hospitalizations rate, decrease the clinical disease activity, and 
need for therapy (Birrenbach and Bocker, 2004) and to decrease the need for colon surgery 
(Odes et al., 2001; Cosnes, 2004). For example, smokers with UC who quit smoking experienced 
an increase in disease activity; however, mild disease activity and symptom improvements were 
seen in ex-smokers who returned to smoking (de Castella 1982; Motley et al., 1987; Ruda et al., 
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1989; Kuisma et al., 2004).  The etiopathology of UC and underlying mechanism of smoking in 
UC is still unclear. Smoking and nicotine have multiple actions which can affect gut 
inflammation. It has been demonstrated that cigarette smoking decreased intestinal permeability 
in healthy volunteers (Prytz et al., 1989; Suenaert et al., 2000); however, UC disease in smokers 
did not demonstrate intestinal permeability decrease when compared with the nonsmokers 
(Benoni and Prytz, 1998) which is most likely to occur in UC patients, since smoking cigarette is 
protective in UC.   
1.5. The Effectiveness of Nicotine Replacement Therapy in Ulcerative Colitis patients 
   Although cigarette smoke contains hundreds of substances, there is evidence that nicotine 
and its metabolites account for the beneficial effect of smoking. However, since nicotine is 
metabolized to cotinine (> 80%) and other metabolites (Benowitz, 1998; Gorrod and Jacob, 
1999), it is possible that these latter metabolites account, at least in part, for the protective 
effect of smoking in UC. Nicotine has shown UC symptoms improvement in some clinical 
trials with different formulations including gum (43% of 7 patients, Lashner et al., 1990), 
transdermal patches (78% of 18 patients, Srivastava et al., 1991; 70% of 10 patients, 
Guslandi and Tittobello, 1996), and enema (71 and 73% of 7 and 22 patients, respectively; 
Sandborn et al., 1997; Green et al., 1997 respectively), although it has some few adverse 
effects which included nausea, headache and sleep disturbance (Pullan et al., 1994; 
McGilligan et al., 2007). Since most of the previous clinical studies showing nicotine 
replacement therapy in humans, including nicotine gum, transdermal and enemas, decreases 
the UC disease activity, but with inconsistent and conflicting results due to the different 
nicotine formulas, various doses of nicotine, duration of the studies, type of the studies, and 
number of subjects in these studies, and their interpretation has been confounded by the side 
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effects experienced by individuals as a result of the high systemic nicotine concentrations 
required (Pullan et al., 1994; Cosnes et al., 2004; McGilligan et al., 2007). In addition, 
nicotine in different formulations including gum, patches, and enema, was not effective in 
treating disease relapses and remission (Perera et al., 1984; Thomas et al., 1996; Ingram et al., 
2005). Furthermore, clinical studies conducted by Green et al., (1997) and Sandborn et al. 
(1997) tested nicotine enemas, in which nicotine is applied directly to the colon, indicated 
that UC symptoms, endoscopic features, and histologically-revealed damage were improved 
with only a few of the patients reporting some side effects.  These initial studies indicate that 
nicotine applied directly to the colon, perhaps in an enema formulation, may be beneficial 
while causing fewer side effects.   
1.6.  The Effectiveness of Nicotine treatment in Experimental Animal Colitis Model 
Similar findings with nicotine have been reported in rodent models of colitis.  For example, low 
doses of oral nicotine treatment (12.5 µg/ml) improved the macroscopic and inflammatory 
damage of experimental colitis in rats, but not with the high doses (250 µg/ml) (Eliakim et 
al.,1998, 2001). A similar observation has been reported by Qiu et al., (1997), in which they 
showed that low doses of oral nicotine (5-20 µg/ml) reduced colonic damage and MPO activity; 
whereas,  at dose of 50 µg/ml increased ulceration area and MPO activity in rats.  Ghia et al., 
(2006) reported also that 20 µg/ml of nicotine in drinking water decreased clinical signs of 
inflammation and reduced colonic myeloperoxidase (MPO) activity and TNF-α levels in the 
mouse DSS model.  However, chronic intraperitoneal injection of nicotine (0.25 and 2.50 
µmol/kg) in DSS-induced colitis in mice failed to decrease clinical signs of inflammation, 
colonic TNF levels and histological features of the disease (Snoek et al., 2010). Although 
experimental studies indicate that the beneficial effects of nicotine in UC is due to its anti-
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inflammatory effect by decreased pro-inflammatory cytokines production in healthy subjects and 
active UC patients (Madretsma et al., 1996; Bhatti and Hodgson, 1997; Louvet et al., 1999; 
Eliakim and Karmeli, 2000; Sykes et al., 2000), nicotine alters adherent mucus thickness in 
rabbits colonic mucosa; reduced by low doses and increased by high doses of nicotine in control 
animals (Zijlstra et al., 1994). In experimental animal models of colitis, nicotine also has been 
shown to be effective in the treatment of intestinal inflammation (Sykes et al., 2000; Eliakim and 
Karmeli, 2003).  Overall, both clinical and animal studies with nicotine treatment suggest the 
usefulness of nicotine in UC disease activity.  
1.7.  The Concept of “Cholinergic Anti-inflammatory Pathway” and involvement of α7 
nicotinic Receptor 
      Many studies reported that the central nervous system (CNS) can regulate the innate immune 
responses through the peripheral nervous system (PNS) (Gallowitsch-Puerta and Tracey, 2005; 
Czura and Tracey, 2005; Pavlov and Tracey, 2006; Gallowitsch-Puerta and Pavlov, 2007). Since 
cholinergic fibers innerve many lymphoid organs, for example, the immune organ thymus, 
express α7 (Navaneetham et al., 1997), also α3 and α5 nicotinic receptors subunits (Mihovilovic 
and Roses, 1991 and 1993) which are expressed by thymocytes. Nicotinic receptors may mediate 
the immune-modulatory effect of nicotine (Conti-Fine et al., 2000), the presence of nAChRs on 
immune cells might play a role in the interaction between the nervous and immune systems 
(Battaglioli et al., 1998; Kawashima and Fujii 2000; 2003; Fujii, 2004).  
      The anti-inflammatory effect of nicotine is also supported by the finding that nicotinic 
receptors can regulate inflammation locally and systemically primarily through the vagus nerve 
so-called “cholinergic (nicotinic) anti-inflammatory pathway” which is a link between 
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parasympathetic and innate immune system and is one of the main endogenous regulatory 
mechanism to control the innate immune responses and ameliorates systemic inflammation by 
regulating the production of pro-inflammatory cytokines mainly through activation of α7 
nAChRs on macrophages surface (Borovikova et al., 2000; Tracey et al., 2001, 2002; Wang H et 
al., 2003, 2004; Ulloa, 2005; de Jonge and Ulloa, 2007). It is reported that nicotinic acetylcholine 
receptor, especially α7 subunit plays an essential role in the cholinergic anti-inflammatory effects 
(Kelso et al., 2006; Hamano et al., 2006).  Other studies reported that vagus nerve activation 
attenuates intestinal inflammation via α7 nAChRs in animal model of postoperative ileus (de 
Jonge et al., 2005) and in experimental colitis (Ghia et al., 2006; 2007). Moreover, α7 nAChR 
agonists has shown anti-inflammatory effects in various animal models of inflammation (Damaj 
et al., 2000; Giebelen et al., 2007), peritoneal macrophages and in human whole blood (Li J et al., 
2011), in a murine endotoxemia and severe sepsis model (Pavlov et al., 2007), and decreased 
severity of experimental pancreatitis (van Westerloo et al., 2005). These anti-inflammatory 
effects appear to be mediated by the activation of α7 nAChRs on immune cells such as 
macrophages in human (Wang et al., 2003; 2004) and mice (Wang et al., 2003; 2004; 
Kawashima et al., 2007).  
       Nicotine is a full agonist at α7 nAChRs (Gerzanich et al., 1995; and Feuerbach et al., 2005). 
α7 nAChRs form homo-pentameric subtypes in the CNS and peripheral nervous system 
(Couturier et al., 1990; Keyser et al., 1993; Sharples and Wonnacott, 2001). α7 subtype is a well-
characterized nAChR subunit (Sharma et al., 2008) and exhibits distinct physiological and 
pharmacological profiles relative to other nAChR subtypes. It is characterized by its high 
calcium permeability (Shen and Yakel, 2009), the rapid desensitization after agonist activation, 
and the blockade by methyllycaconitine and α-bungarotoxin (for reviews, Dajas-Bailador and 
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Wonnacott, 2004; Hogg and Bertrand, 2004). Previous studies demonstrated that α7 nAChR 
subunits express on macrophages can inhibit transcriptional activity of NF-κB, hence decrease 
the release of pro-inflammatory cytokines (Nizri et al., 2006; Yoshikawa et al., 2006; Parrish et 
al., 2008). During inflammation, activation of α7 nAChRs is associated with calcium influx and 
inhibits activation of nuclear factor κB (NF κB) (Borovikova et al., 2000; Tracey et al., 2005; 
2009). From our previous study (Abdrakhmanova et. al., 2010), we showed that in vitro nicotine 
suppressed firing of action potential in colonic sensory neurons from DSS-treated mice. 
Moreover, we showed that nicotine fails to suppress multiple-spike action potential firing in 
inflamed mouse neurons in the presence of the α7 competitive antagonist MLA, which was 
confirmed by using natural α7 agonist choline chloride which suppressed hyper excitability of 
inflamed colonic sensory neurons which support the essential role of α7 nAChRs in the 
mechanism of nicotine-induced suppression of action potential firing in inflamed colonic 
neurons. Since α7 nicotinic receptors involve in the cholinergic anti-inflammatory pathway 
(Wang et al., 2003; de Jonge et al., 2005; Ulloa, 2005) and earlier studies reveal the important 
role of α7 nAChRs in controlling gut inflammation, using selective α7 agonists and a positive 
allosteric modulator for α7 nAChRs could open a new therapeutic avenue and represent a 
promising pharmacological strategy for the treatment of inflammation in ulcerative colitis.  
1.8. Nicotinic Receptors: Composition, Distribution, and Subtypes  
       Neuronal nicotine acetylcholine receptors (nAChRs) are pentameric ligand-gated ion 
channels that exist as homomeric or heteromeric complexes of α and β subunits. To date, 12 
neuronal subunits (α2-α10 and β2-β4) have been identified in mammals (see Gotti et al., 2007 for 
review). Nicotine exerts its effects by activating nicotine acetylcholine receptors. Nicotinic 
receptors are found in nerves of the central and peripheral nervous systems and in the autonomic 
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ganglia, colonic submucosal and myeteric plexuses. They are also present in non-neuronal cells 
including human immune cells. Human lymphocytes express mRNA for nAChR subunits for α3, 
α4 (Hiemke et al., 1996), α3, α5, and β4 (Mihovilovic et al., 1998; Mihovilovic and Roses, 1991, 
1993). Human mononuclear leukocytes expressed mRNAs encoding the α2, α5, and α7 subunits 
(Sato et al., 1999). They are expressed in the enteric nervous system, in enteric plexuses 
(Kirchgessner and Lu, 1998; Obaid et al., 2005). For example, many nAChR subunits mRNA for 
α3, α5, α7, β2, and β4 have been detected in the intestine (Kirchgessner and Lu, 1998; Obaid et 
al., 1999a,b; Obaid and Lindstrom, 2000).  Nicotinic receptors have been identified in colonic 
epithelial HT29 cells, including α3, α5, α7 nAChR subunits (Summers et al., 2003).  α7 nAChRs 
form homo-pentameric subtypes in the central nervous system (CNS) and peripheral nervous 
system (PNS) (Couturier et al., 1990; Keyser et al., 1993; Sharples and Wonnacott, 2001). 
Although these receptors are predominantly expressed in neuronal tissues, several types of 
immune cells express α7 nAChR mRNA, including macrophages (Tracey, 2002; Kawashima et 
al., 2007 and Rosas-Ballina et al., 2008), T-cells (Fujii et al., 1999), B-cells (Fujii et al., 1999; 
Sato et al., 1999), microglia (Shytle et al., 2004), monocytes (Matsunaga et al., 2001; 
Kawashima et al., 2007) and dendritic cells (Aicher et al., 2003; and Kawashima et al., 2007) and 
express on endothelial cells (Wang Y et al., 2001; Abbruscato et al., 2002; Moccia et al., 2004; 
Saeed et al., 2005; Kawashima et al., 2007). α9 subunit can form functional homopentamer  
nicotinic receptors (Elgoyhen et al., 1994) and functional heteromeric with α10 subunits 
(Elgoyhen et al., 2001; Sgard  et al., 2002). α9 and α10 subunits have  restricted anatomical 
tissue expression (Nashmi and Lester, 2006; Gotti et al., 2006). They have not been detected in 
the brain and spinal cord (Elgoyhen et al., 2001; Sgard F et al., 2002). Gene transcripts for α9 or 
α10 have been reported within hair cells of the inner ear (Elgoyhen et al., 1994; Elgoyhen et al., 
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2001; and Vetter et al., 2007), skin keratinocytes (Arredondo J et al., 2002), in the sperm (Kumar 
and Meizel, 2005), dorsal root ganglion (DRG) neurons (Lips et al., 2002), the pars tuberalis of 
the pituitary (Sgard et al., 2002), and lymphocytes (Peng H et al., 2004).  α10 is expressed in 
arteries (Bruggmann et al., 2002; 2003) and sympathetic ganglia (Lips et al., 2006). The 
functional significance of α9 and α10 in these tissues is not known. Finally, both α9 and α10 are 
present in many immune cells (Lustig et al., 2001, Peng et al., 2004; Galvis et al., 2006; 
Kawashim et al., 2007; Wessler and Kirkpatrick, 2008). The α9 and α10 nAChR subunits have 
been detected in human cultured T cells, blood lymphocytes, in monocytes, and macrophages 
(Lustig et al., 2001, Peng et al., 2004; Galvis et al., 2006; Kawashim et al., 2007). However, the 
functioning of α9α10 nAChRs in the immune cells is not clear. 
1.9. Animal Experimental Models of Colitis 
   Inflammatory bowel disease (IBD), includes Crohn’s disease (CD) and ulcerative colitis (UC), 
results from chronic dysregulation of the mucosal immune system in the gastrointestinal tract, 
and it is widely accepted that genetic, environmental, and immunological factors are involved. 
Although the pathogenesis of IBD remains unclear, animal models of intestinal inflammation 
have provided critical perceptions and investingating various factors involve into the 
pathogenesis of colitis (Blumberg et al., 1999; Strober et al., 2002) and evaluating different 
therapeutic agents. Several models of experimental colitis that demonstrate various 
pathophysiological aspects of the human IBD have been described such as dextran sodium 
sulfate (DSS), trinitrobenzene sulfonic acid (TNBS), acetic acid, indomethacin, and oxazolone-
induced colitis models. Here, we induced colitis in mice using dextran sulfate sodium (DSS) 
which is one of the best described models of UC and a widely used animal model of colitis. It 
has been used over 20 years (Ohkusa et al., 1985) due to its simplicity. In addition,  it has some 
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advantages over other experimental colitis models; for instance, different stages of the disease 
conditions, acute, chronic, or relapsing condition can be induced by simply modulating DSS 
concentration in the drinking water  (animals stress-free handling) and importantly shows some 
resemblance of human UC in both clinical (body weight loss, loose stool, bloody diarrhea or 
rectal irritation and hematochezia) and histopathologic findings (Okayasu et. al., 1990; Takizawa 
et. al., 1991; Cooper et al., 1993; Gaudio et. al., 1999), and is characterized by an excessive T 
helper 2 (Th2) cell response (Targan and Karp, 2005). The responsiveness of the DSS-induced 
colitis model to conventional therapeutic agents for human UC supports its suitability as a model 
of human UC and help to translate basic research to clinical practice (Böjrck et. al., 1997). 
However, using DSS-induced colitis model, various factors may affect the responsiveness to 
DSS; such as, concentration of DSS used in the experiment (Egger et al., 2000), duration of 
exposure, molecular weight of DSS (Kitajima et al., 2000; Hirono et al., 1983), animals strain 
and sex differences (Mahler et al., 1998). Thus, all these factors should be considered during 
study design before conducting the experiment.  
1.10. Using Genetically Modified Animals: a complementary approach to study the role of    
nAChR subtypes in murine colitis model 
The use of knock-out mice for different nicotinic receptor subunits is an attractive approach to 
overcome the limitation of the availability and/or selectivity of nicotinic receptor ligands.  
Importantly, this approach helps to elucidate the role of specific nicotinic receptor subtypes and 
provides a powerful tool to confirm results derived from pharmacological studies. . Overall, the 
use of genetically modified animals and knockout technology offers many advantages that 
cannot be achieved through the use of pharmacological agents that can be utilized as 
complementary tools to insight the specific functional role of certain nicotinic receptor subunit. 
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The KO mouse is typically engineered using mouse embryonic stem (ES) cells from the 129/Sv 
inbred mouse. The gene of interest is inactivated by replacement of coding sequences essential 
for gene function with a neomycin cassette. Through homologous recombination, the normal 
gene on the chromosome is replaced with the targeted cassette, thus “knocking out” the gene 
function. These engineered stem cells from the 129/Sv mouse that contain the homologous 
recombination construct are then injected into C57Bl/6 (B6) mouse blastocysts, and implanted 
into a foster mother; thus, the pups born from this event are composed of cells from a B6 embryo 
and 129/Sv stem cells. The resulting chimeric mice that contain the mutated embryonic stem 
cells are then mated with B6 mice to allow the mutation of the KO allele to pass onto the next 
generation, the resulting mice will be heterozygote that can be inter bred to generate 
homozygous mutant KO mice and ultimately generate KO mice in later generations. To date, 
several nAChR KO mice have been generated and the phenotypes have been characterized. Here 
in our studies we used α5 (Salas et al., 2003), α7 (Orr-Urtreger et al., 1997), β2 (Picciotto et al., 
1995). One major limitation to KO studies is the compensatory mechanisms in knockout mice, 
and the occurrence of developmental requirements that may occur as a result of gene deletion, 
and can interfere with interpretation of results. It may be difficult to determine if the mouse 
phenotype is a result of the gene deletion. The backcrossed of these knockout mice for 10 
generations with C57BL/6 mice could help reduce the possibility that mixed genetic of mutant 
mouse background.  
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1.11. Dissertation Objectives 
Using DSS-induced experimental colitis model in male C57BL/6J mice: 
- To characterize the dextran-sulphate sodium (DSS)-induced colitis model in mice. 
- To investigate the effect of the main active substance of tobacco, nicotine and its 
main metabolites, cotinine, in a DSS-induced colitis model.   
- To examine if dose and route of nicotine administration have a role in ameliorating 
DSS-induced colitis model.  
- To examine the role of α7 nAChRs in mouse DSS-induced colitis model using 
pharmacological tools by examing the effect of chronic treatment of α7 agonists, 
PHA-543613, choline and the positive allosteric modulator for α7 nicotinic receptor, 
PNU 120596 and confirm our results using genetically modified animals, α7 KO mice. 
- Finally, to assess the specificity of the involvement of α7 nAChRs by investingating 
the role of non-α7 nAChRs including α5, α9, α10 and β2 nAChRs in DSS colitis 
model. 
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CHAPTER TWO 
Materials and Methods 
2.1. Animals  
Male C57BL/6J, α5, α7 knockout mice were purchased from Jackson Laboratories (Bar Harbor, 
ME). Mice null for the β2 subunit were provided from Institut Pasteur (Paris, France). The null 
mice and their wild-type littermates were bred in an animal care facility at Virginia 
Commonwealth University (Richmond, VA, USA) and are maintained on a C57Bl/6 background 
and have been backcrossed to at least N10. For all experiments, mutants and wild type controls 
are obtained from crossing heterozygote mice. This breeding scheme allows us to rigorously 
control for any anomalies that may occur with crossing solely mutant animals. Male animals 
were 8-10 weeks of age at the start of the experiments, weighing 25-30 g and were group-housed 
in a 21°C humidity-controlled Association for Assessment and Accreditation of Laboratory 
Animal Care-approved animal care facility with ad libitum access to food and water. Mice were 
housed under standard conditions for a minimum of 1 week before experimentation. Experiments 
were performed during the light cycle and were approved by the Institutional Animal Care and 
Use Committee of Virginia Commonwealth University. 
2.2. Drugs 
(-)-Nicotine hydrogen tartrate salt [(−)-1-Methyl-2-(3-pyridyl) pyrrolidine (+)-bitartrate salt] and 
(-)-cotinine were purchased from Sigma-Aldrich Inc. (St. Louis, MO). DSS (molecular weight 
36-50,000 kilodaltons) was obtained from ICN Biomedicals Inc. (Aurora, OH). Nicotine doses 
are expressed as the free base of the drug. PHA-543613,(N-[(3R)-1-Azabicyclo[2.2.2]oct-3-
yl]furo[2,3-c]pyridine-5-carboxamide Dihydrochloride) and PNU-120596 (1-(5-chloro-2,4-
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dimethoxy-phenyl)-3-(5-methyl-isoxanol-3-yl)-urea) were obtained from the drug supply 
program of the National Institute on Drug Abuse (Rockville, MD). PHA-543613 was dissolved 
in physiological saline (0.9% sodium chloride) and administered by subcutaneously twice daily. 
PNU-120596 was suspended in a vehicle of absolute ethanol, Emulphor-620 (Rhone-Poulenc, 
Inc., Princeton, NJ), and saline at a ratio of 1:1:18 and administered by i.p. injection once daily at 
a volume of 10 ml/kg body weight unless noted otherwise. Doses are expressed as the free base 
of the drug. Choline chloride (Sigma-Aldrich) was dissolved in the drinking water and given 
orally. DSS at different concentrations was dissolved in the drinking water and given orally. The 
doses of PHA-543613, PNU 120596, and choline chloride were chosen based on previous data 
(Wishka et al., 2006; Krafft et al., 2012; Hurst et al., 2005; Ghia et al., 2009). α-Conotoxin-RgIA 
(α-RgIA), a selective α9* antagonist,  (provided from Dr Michael McIntosh, University of Utah) 
(0.1, 0.2, and 0.02 mg/kg once daily) treatment started 3 days before and for 7 days after the 
induction of colitis. α-RgIA, was dissolved in physiological saline (0.9% sodium chloride) and 
administered by subcutaneous (s.c.) injection at a volume of 10 ml/kg body weight. Molecular 
mass of RgIA is 1572 daltons. In addition, we conducted a dose-response curve for each drug in 
DSS-induced colitis model in mice. 
2.3. Dextran Sulphate Sodium (DSS)-induced colitis model:  
DSS was added to the drinking water at different concentrations (in % w/v) for 7 days in most 
experiments. On day 8, mice received drinking water without DSS. Controls were all age- and 
time-matched and consisted of mice that received regular tap drinking water for the 
corresponding number of days.  Each treatment group consisted of 8-10 mice.  
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2.4. Assessment of the Severity of Colitis: Disease Activity Index 
Disease Activity Index (DAI) scores historically have correlated well with the pathologic 
findings in a DSS-induced model of IBD (Cooper et al., 1993). DAI is the combined score of 
four clinical parameters, including a) weight loss, b) stool consistency, c) rectal irritation, and d) 
blood in the stool. Scores were defined as follows: for weight: 0, no loss; 1, 5%–10%; 2, 10%–
15%; 3, 15%–20%; and 4, 20% weight loss; for irritation around the anal area; 0, normal; 1, mild 
irritation; 2, moderate irritation; 3, severe irritation; for stool: 0, normal; 1, mild loose stool; 2, 
moderate loose stool and 3, diarrhea; and for bleeding: 0, no blood; 1, presence of blood 
(Hemoccult II positive; Beckman Coulter, Fullerton, CA); and 2, gross blood. DAI symptoms 
were recorded same time of every day and scored from days 0–8 in blinded manner to the 
treatment and mouse genotypes. Total DAI score ranged from 0-12. On day 8, after replacing the 
DSS with water, the mice were sacrificed and the abdominal cavity was opened, the entire colon 
was immediately removed and the colon length (cm) measured.   
2.5. Colonic Histology Assessment 
  Seven days after the beginning of the DSS treatment, two-three mice of each group were 
sacrificed and the colon was removed. Formalin-fixed colon segments were paraffin-embedded 
and 3-µm sections were stained with haematoxylin-eosin (H&E). Colonic damage was scored 
based on a published scoring system that considers architectural derangements, epithelium 
changes, goblet cell depletion, ulceration, and degree of inflammatory cells infiltrate in a blinded 
fashion (Iba Y et al., 2003). The histological scoring system was used to evaluate the degree of 
colitis. The total histological score ranged from 0 to 12, which represented the sum of scores 
from 0 to 3 (0= none, 1= 0-5 %, 2= 5-10%, 3= > 10%) for loss of epithelium, (0= none, 1= 0-
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10 %, 2= 10-20%, 3= > 20%) for crypt damage, (0= none, 1= mild, 2= moderate, and 3= severe) 
for each of depletion of goblet cells and infiltration of inflammatory cells. Each section was 
scored for each feature separately by establishing the product of the grade for that feature and the 
percentage involvement in the loss of epithelium and crypt damage features (in a range from 0 to 
3 for each feature). The number of inflammatory cells infiltration in 10 randomly selected power 
fields (40X) was counted and the number per 10 fields was calculated. The scores were assigned 
by one experienced histopathologist with no knowledge of the group being examined in each 
analysis. The histological colitis score of individual mice represents the sum of the different 
histological subscores. Light microscope images were acquired with an Axioscope AX10 
microscope and Axioviosion 4.6 software (Carl Zeiss, Inc.). Mean ± SE, n=3 animals were used 
per group. 
2.6. Assessment of Colonic Myeloperoxidase (MPO) Activity:  
The colonic tissues were homogenized with a homogenizer in phosphate buffered saline (PBS) 
for the assessment of MPO. Tissue samples were homogenized in 100 mM sodium acetate (pH 
6.0) containing 0.5% hexadecyl trimethyl ammonium bromide and 5 mM EDTA. The 
homogenate was briefly sonicated, and then centrifuged at 13000 rpm for 10 min at 4° C. The 
supernatant was then added to a homogenizer solution in 96 well plate. 75 µl of 3,3’5,5’-
tetramethylbenzidine (TMB) substrate were added to each well and the plates were incubated for 
2 min; 50 µl of stop solution (2N H2SO4) were then added. The plates were read at 450 nm 
within 30 min. For each mouse, a semilog curve of sample dilution vs. optical density (O.D.) was 
plotted to obtain a midpoint titer.  Mean ± SE, n=5-8 animals were used per group. 
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2.7. Tumor necrosis factor-alpha (TNF-α) Levels: 
The colonic sample was homogenized in 1 mL of Tris-HCl buffer containing protease inhibitors 
(Sigma-Aldrich Inc., St. Louis, MO, USA). Samples were centrifuged then centrifuged (1811 x g, 
5 min) at a temperature of 4°C, and the supernatant was frozen at - 80°C until assay. The protein 
concentration was determined by the Bradford assay (Bradford, 1976). Cytokine level (TNF-α) 
was determined using an enzyme-linked immunosorbent assay commercial kit (Quantikine M 
murine; R&D Systems, Minneapolis, MN). 
2.8. Total Protein Quantification 
The Bradford protein assay was used to determine the total protein content in the supernatant.  
We have chosen the most widely used protein as our standard - Bovine Serum Albumin (BSA). 
The assay is based on the proportional binding of the dye Coomassie to proteins. 2 µl of 
supernatant was added to 750 µl of Bradford reagent (Sigma) at room temperature. The 
absorbance at 595 nm was measured and the protein concentration determined using a standard 
curve. 
2.9. Nicotine and Cotinine Plasma Levels:  
Blood samples were taken from mice receiving different protocols of nicotine: 10 days after oral 
(-)-nicotine or (-)-cotinine administration in the drinking water, 2 weeks after continuous 
minipump (-)-nicotine infusion (2.5 and 25 mg/kg) and 5 min after the last s.c. injection of 
chronic nicotine injection (0.5 and 2 mg/kg) (Tables 4 and 5).  Animals were anesthetized with 
CO2, blood samples were taken by intra-cardiac puncture just before death and blood was kept in 
sodium heparin blood collection tubes, and centrifuged (1400 x g, 10 min). The serum then was 
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stored at - 4ᵒC.  Nicotine and cotinine serum levels were measured using HPLC/MS/MS analysis. 
At least 6 animals were used per group. 
2.10. Nicotine and metabolites HPLC/MS/MS analysis: 
Specimen extraction: To a 200 µL aliquot of whole blood, 50 µL of internal standard (ISTD) 
containing 50 ng of nicotine-d4 and cotinine-d3 in methanol was added with mixing. Then 100 
µL of 5M ammonium hydroxide was added to each sample followed by 2ml methylene chloride.  
The samples were mixed for 2 minutes and then centrifuged (1811 x g, 5 min) at a temperature 
of 4°C.  The organic layer was transferred to a clean test tube.  The aqueous phase was extracted 
twice more with 2 mL of methylene chloride.  The organic phases were combined and 500 µL of 
25mM HCl in methanol was added.  Samples then were evaporated to dryness under a gentle 
stream of nitrogen. They were reconstituted with 100 µL of mobile phase and placed in auto-
sample (HPLC/MS/MS) vials for analysis. 
Instrumental Analysis: The HPLC/MS/MS system used was an Applied Bio systems 3200 Qtrap 
with a turbo V source for TurbolonSpray with a Shimadzu SCL HPLC system controlled by 
Analyst 1.4.2 software. The chromatographic separation was performed using a Hypersil Gold, 
3mm X 50 mm, 5 micron (Thermo Scientific, USA).  The mobile phase contained 10 mM 
ammonium formate; methanol (10:90 V/V) and was delivered at a flow rate of 0.5 mL/min. The 
acquisition mode used was multiple reaction monitoring (MRM) in a positive mode. Transition 
ions monitored for nicotine (163>130; 163>117), nicotine-d4 (167>134), cotinine (177>80; 
177>98) and cotinine-d3 (180>80).  The total chromatographic separation time for each extract 
injection was 2 minutes. A calibration curve ranging from 12.5 ng/ml to 500 ng/ml was 
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constructed for each compound based on linear regression using the peak area ratios of the drug 
to its deuterated ISTD. Cotinine-d3 also was used as the ISTD for 3-hydroxycotinine.  
2.11. Statistical Analysis.  Statistical analysis of all studies was performed with ANOVA. Two-
way repeated-measures ANOVAs were used at the different time points. Significant overall 
ANOVA were followed by Tukey’s test post hoc test when appropriate. All differences were 
considered significant at *p<0.05. The GraphPad Prism® program was used for data 
manipulations, graphical representations, and statistical analysis (GraphPad Software Inc., San 
Diego, CA). Clinical, histological, cytokine data are presented as mean ± SE at different 
treatments and time points (n=6-8 animals for clinical DSS results, n=3 per group for histological 
results, n=5-8 animals for MPO and cytokine measurements). 
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CHAPTER THREE 
The Impact of Nicotine Route of Administration in Murine DSS-induced Colitis 
Background and purpose. Studies have shown that nicotine has a positive influence on 
symptoms of ulcerative colitis (UC). In the present study, we explored the effect of nicotine 
treatment using different route of administrations in the DSS colitis mouse model.  We also 
investigated the effects of cotinine, a major metabolite of nicotine, in the model. 
Experimental approach. C57BL6 male adult mice were given DSS solution at different 
concentrations freely in the drinking water for 7 consecutive days after which tap water was 
given on the 8th day. Disease severity, length of the colon, colon tissue histology, inflammatory 
markers including colonic myeloperoxidase (MPO) activity and colonic tumor necrosis factor-α 
(TNF-α) levels were then evaluated. The effect of oral, subcutaneous, infusion of nicotine, and 
oral cotinine treatments were examined the DSS model. In addition, we measured the plasma 
levels of the nicotine and cotinine in our treatment protocols. 
Key Results. Administration of low, but not high, doses of oral nicotine in DSS-treated mice 
produces a significant decreases in DAI severity, histological damage scores, as well as colonic 
level of TNF-α. However, the anti-inflammatory effect of nicotine was not seen after chronic s.c. 
and infusion of the drug. Differences in plasma levels of nicotine and cotinine do not seem to 
account for this lack of effect. Finally, cotinine oral administration on its own failed to show a 
significant effect in the DSS model of colitis.  
Conclusions and Implications. Results obtained from this study highlight that dose and route of 
administration play a critical role in the protective effect of nicotine in the DSS mouse colitis 
model.  
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3.1. Introduction 
  Ulcerative colitis (UC) is a chronic inflammatory bowel disease of unknown etiology, 
due partly to genetic susceptibility to environmental factors that misdirect the mucosal immune 
system response to attack the epithelial layer of the colon causing inflammation. UC is a 
remitting and relapsing inflammatory condition that results in excessive mononuclear cell and 
neutrophil infiltration into mucosa and submucosa vicinities that affects primarily the distal 
colon and rectum (Hanauer, 1996).  Patients typically present with bloody diarrhea and passage 
of pus and/or mucus that often persists for months and is accompanied by abdominal cramping 
during bowel movements. Current pharmacotherapies, which include 5-aminosalicylic acid drugs 
and glucocorticoids, have poor efficacy and many adverse effects that limit their use (Rosenberg 
and Peppercorn, 2010).  It is, therefore, highly desirable to develop more efficacious treatments 
that elicit fewer side effects than presently used medications.  
UC has been linked to tobacco smoking for more than three decades.  For example, 
smokers with UC who quit smoking experienced an increase in disease activity; however, mild 
disease activity and symptom improvements were seen in ex-smokers who returned to smoking 
(de Castella 1982; Motley et al., 1987; Ruda et al., 1989; Kuisma et al., 2004).  Moreover, 
tobacco smoking has been reported to often have a beneficial outcome on the course of activity 
of UC in smokers (Boyko et al., 1988; Mokbel et al., 1998; Gheorghe et al, 2004; Höie et al., 
2007) and to decrease the need for colon surgery (Odes et al., 2001; Cosnes J, 2004).  Although 
cigarette smoke contains hundreds of substances, there is evidence that nicotine accounts for the 
beneficial effect of smoking.  However, since nicotine is metabolized to cotinine (> 80%) and 
other metabolites, it is possible that these latter metabolites account, at least in part, for the 
protective effect of smoking in UC.  
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A number of clinical studies has been carried out in which nicotine was administered in 
different formulations using patches and gums to UC patients.  Nicotine has shown positive 
results on disease symptomology in some trials. Nevertheless, results have been conflicting and 
interpretation has been confounded by side effects experienced by individuals as a result of the 
high systemic nicotine concentrations required (Pullan et al., 1994; Cosnes et al., 2004; 
McGilligan et al., 2007).  In addition, it has been indicated that nicotine lacks efficacy in treating 
disease relapses and remission (Perera et al., 1984; Thomas et al., 1995; Ingram et al., 2005).  
Thus, collectively these results indicate that, while transdermal nicotine may be effective for UC 
especially in ex-smokers, its use is limited by its adverse event profile.  However, it is not clear if 
the delivery of nicotine through patches and gum formulations, which do not mimic the 
intermittent delivery of nicotine from cigarettes, plays a role in the efficacy of the drug.  
Furthermore, clinical studies conducted by Green et al., (1997) and Sandborn et al. (1997) tested 
nicotine enemas, in which nicotine is applied directly to the colon, indicated that UC symptoms, 
endoscopic features, and histologically-revealed damage were improved with only a few of the 
patients reporting some side effects.  These initial studies indicate that nicotine applied directly 
to the colon, perhaps in an enema formulation, may be beneficial while causing fewer side 
effects.   
Similar findings with nicotine have been reported in rodent models of colitis.  For 
example, oral nicotine treatment improved the macroscopic damage of experimental colitis 
(Eliakim et al., 2001).  Ghia et al., (2006) reported also that 20 µg/ml of nicotine in drinking 
water decreased clinical signs of inflammation and reduced colonic MPO activity and TNF-α 
levels in the mouse DSS model.  However, chronic intraperitoneal injection of nicotine (0.25 and 
2.50 µmol/kg) in DSS-induced colitis in mice failed to decrease clinical signs of inflammation, 
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colonic TNF levels and histological features of the disease (Snoek et al., 2010).   
In the present study, we used the DSS mouse model, one of the best described and widely 
used animal models of UC since it shows some resemblance to human UC in both clinical (body 
weight loss, loose stool, bloody diarrhea or rectal irritation and hematochezia) and 
histopathologic findings (Okayasu et. al., 1990; Takizawa et. al., 1991; Cooper et al., 1993; 
Gaudio et. al., 1999). Furthermore, the model is characterized by an excessive T helper cell 
response (Targan and Karp, 2005). The responsiveness of the DSS-induced colitis mouse model 
to conventional therapeutic agents for human UC supports its suitability as a model of human 
UC (Böjrck et. al., 1997). We examined the effect of chronic nicotine administration using 
various doses and routes of administration (subcutaneous, infusion using osmotic minipump, and 
oral) in order to define the optimal route and dose that resulted in ablation of DSS-induced colitis 
model in the mouse. We also tested the effect of one of the main nicotine metabolites, cotinine, 
in order to garner insight as to whether it contributes to the beneficial effect of cigarette smoking 
in UC patients. 
3.2. Materials and Methods 
See chapter 2 
3.2.1. Drugs 
(-)-Nicotine hydrogen tartrate salt [(−)-1-Methyl-2-(3-pyridyl) pyrrolidine (+)-bitartrate salt] and 
(-)-cotinine were purchased from Sigma-Aldrich Inc. (St. Louis, MO). DSS (molecular weight 
36-50,000 kilodaltons) was obtained from ICN Biomedicals Inc. (Aurora, OH). Doses are 
expressed as the free base of the drug. 
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3.3. Chronic nicotine treatment 
DSS-induced colitis model: DSS was added to the drinking water at 1%, 2.5% and 5% 
concentrations (in % w/v) for 7 days. On day 8, mice received drinking water without DSS. 
Controls were all age- and time-matched and consisted of mice that received regular tap drinking 
water for the corresponding number of days.  Each treatment group consisted of 8-10 mice.  
3.3.1. Study 1. Dextran sulfate sodium (DSS) dose response curve.  Separate group of mice 
were allocated to the following treatments: controls (water only), 1% DSS, 2.5% DSS and 5% 
DSS for 7 days.  
3.3.2. Study 2.  Effect of Oral (-)-nicotine administration.  Different doses of (-)-nicotine (6, 
12.5, 25, 50, and 100 µg/ml) were added to the drinking water 3 days before and for 7 days along 
with the induction of colitis with DSS 2.5%.  
3.3.3. Study 3.  Effect of s.c. (-)-nicotine administration. Saline or (-)-nicotine treatment (0.1, 
0.5, 2 mg/kg) was given s.c. twice daily for 10 days.  (-)-nicotine was dissolved in physiological 
saline (0.9% sodium chloride) and administered by s.c. injection at a volume of 10 ml/kg body 
weight.  The s.c. nicotine or saline injection was administered 3 days before induction of DSS 
colitis and was continued along with DSS treatment period.  
3.3.4. Study 4.  Effect of (-)-nicotine administration through mini pump. Nicotine was infused 
for 14 days though osmotic mini pump at doses of 2.5 and 25 mg/kg/day. Mice were implanted 
with Alzet osmotic mini pumps [model 2002 (14 days), Durect Corporation, Cupertino, CA] 
filled with (-)-nicotine or saline solution. The concentration of nicotine was adjusted according to 
animal weight and the mini pump flow rate, resulting in 2.5 and 25 mg/kg/day for 14 days. The 
mini pumps were surgically implanted s.c. under sterile conditions with sodium pentobarbital 
anesthesia (45 mg/ml, i.p.). An incision was made in the back of the animal, and a pump was 
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inserted. The wound was closed with wound clips, and the animal was allowed to recover before 
being returned to its home cage. DSS was added to the drinking water for 7 days in the second 
week of saline or (-)-nicotine minipump implantation. 
3.3.5. Study 5.  Effect of oral cotinine administration.  Two doses of (-)-cotinine (25 and 250 
µg/ml) were added to the drinking water 3 days before and for 7 days along with the induction of 
colitis with DSS 2.5%.  
3.4. Results 
3.4.1. Characterization DSS dose response curve on colitis severity in the mouse 
We first evaluated the colitis severity in the mouse DSS model.  For that, we examined 
the effects of 1, 2.5 and 5% of DSS concentrations in C57BL/6J mice on the disease activity 
scores, colon length, colonic histological damage, colonic MPO activity and colonic TNF-α 
levels.  
Oral DSS administration for 7 days induced signs of colitis in C57BL/6J mice in a dose-
related manner [F (3, 30) =46.12, p<0.0001] as measured by the disease activity scores (Figure 1 
A-C). Mice treated with 1% DSS did not show significant differences in any of the colitis 
parameters including rectal irritation, loose stool, bloody diarrhea and loss in body weight, 
compared with the water-treated control group.  However, both 2.5 and 5% DSS concentrations 
significantly increased all clinical signs of colitis severity.  The loss of body weight was 
significant on day 5 and exhibited a gradual increase in mice receiving 2.5% DSS and 5% DSS 
with a 
˜
 15% loss on day 8 (Figure 1 C).  Similar to disease activity, the decrease in the colon 
length was dose related with all DSS concentrations significantly resulting in reduction in length 
compared to the water-treated control group (Figure 1 D).   
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In general, the increase in the inflammatory markers MPO and the pro-inflammatory 
cytokine TNF-α correlated with the severity of colitis. MPO activity was undetectable in the 
control water-treated animals and was higher in mice-treated with DSS 2.5 and 5% respectively 
[F (3, 14) =7.668, p=0.0029] (Figure 2 A).  The level of TNF-α, an acute inflammatory marker, 
was increased significantly in mice treated with 2.5 and 5 % DSS compared to the control group 
[F (3, 16) = 49.46, p<0.0001] (Figure 2 B).  
The histology of the colon after 7 days of DSS treatment was characterized by multifocal 
changes in crypts with some areas showing focal lesions and inflammatory cell infiltration that 
included neutrophils and lymphocytes. The histological damage was significantly higher in the 
2.5 and 5% DSS group when compared with the control group [F(3, 36) = 36.23, p<0.05] (Figure 
3 E). There were focal changes suggesting a discontinuous appearance of histological features 
with varying severity of epithelial loss (Figure 3 A), shortening of crypts (Figure 3 B), depletion 
of goblet cells (Figure 3 C), and inflammatory cells infiltration (Figure 3 D).  The extent of the 
inflammatory response also was assessed by histology of mucosal tissue using haematoxylin-
eosin staining (Figure 4). DSS-treated mice showed extensive ulceration of the mucosa with 
destruction and inflammation mainly in the mucosa; however, some inflammation to the 
submucosa was seen with 5% DSS as well as shortening of the crypts, and inflammatory cell 
infiltration (Figure 4 D).  Since the 7-day 2.5% DSS administration protocol showed a reliable 
inflammatory colitis with a low rate of mortality compared to the 5% DSS group [30% vs 75% 
for 2.5% and 5%, respectively] after 7 days recovery period post-DSS (Figure 5), it was chosen 
for subsequent studies with nicotine and nicotine ligands. 
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3. 4. 2. Oral nicotine administration attenuates DSS-induced colitis 
Oral nicotine treatment at doses of 12.5, 25 and 50 µg/ml significantly decreased disease 
activity scores during the last three days of DSS disease course [F(3,48) = 6.615, p=0.0021] 
(Figure 6 A).  In contrast, nicotine at the highest dose (100 µg/ml) significantly enhanced disease 
activity scores at day 7 and day 8 compared with the DSS-treated group as seen in the dose-
response curves and area under the curve values [F(2, 19) = 5.593, p=0.0123] (Figure 6 A & B).  
A similar profile was seen with the body weight loss where the effect of nicotine was lost at 
higher doses (Figure 6 C).  All tested doses of oral nicotine treatments did not significantly 
reverse the effect of DSS on the colon length shortening (Figure 6 D).   
Oral nicotine at 25 µg/ml, a dose that attenuated DSS-induced colitis signs, reduced also 
the increase in colonic TNF-α levels seen with DSS-treated mice [F(3,27) = 4.60, p=0.010] 
(Figure 7 A).  However, this effect was lost at the high dose of 100 µg/ml of the drug. In line 
with the disease activity scores, DSS-treated mice showed a significant decrease in histological 
scores after treatment with the low dose of 12.5 µg/ml of nicotine.  However, this effect started 
to gradually decrease with increasing doses (25 and 100 µg/ml) of nicotine (Figure 7 B).  
Furthermore, nicotine oral administration at doses of 12.5 and 25 µg/ml normalized the 
appearance of epithelial architectures of colonic slices and reversed the DSS-induced colonic 
damage (Figure 7 E & F).   
To determine if nicotine is bioavailable in our treatment protocols, the plasma levels of 
the drug and its main metabolite cotinine, were measured using the lowest active dose and 
highest dose of oral nicotine administration in DSS-treated mice. Oral nicotine administration 
resulted in a dose-related increase in the level of plasma levels of nicotine and cotinine (Table 4) 
in DSS-treated mice.  
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3.4.3. Effect of subcutaneous and mini pump nicotine treatments on DSS-induced colitis 
Subcutaneous nicotine treatment (0.1, 0.5 and 2 mg/kg s.c. twice daily for 10 days) was 
evaluated in the DSS model. Overall, nicotine given s.c. failed to alter significantly the intensity 
disease activity in the DSS-treated animals.  Only the low dose of 0.1 mg/kg s.c. resulted in a 
significant decrease in the disease activity on days 7 and 8 (Figure 8 A).  A decrease in the area 
under the curve at the same dose was observed, but it failed to reach statistical significance 
(Figure 8 B) [F (3, 36) = 2.604, p=0.0668)].  Similarly, only mice injected with 0.5 mg/kg s.c. 
showed a significant attenuation in the colon length shortening when compared with the vehicle 
DSS-treated group [F (4, 42) = 20.76, p<0.05] (Figure 8 C).  However, none of the nicotine 
doses tested after chronic s.c. injection showed a significant decrease in total histological damage 
score compared with DSS-treated mice (Figure 8 D).  Similarly, nicotine did not reverse colonic 
TNF-α levels in DSS-treated mice (Table 2).  Finally, chronic administration of 0.5 and 0.1 
mg/kg of nicotine increased the plasma levels of nicotine and cotinine in mice. Drug plasma 
levels after nicotine administration of 0.1 mg/kg were below the level of detection (Table 4).  
Chronic exposure of mice to nicotine via mini pumps infusion at doses of 2.5 and 25 
mg/kg/day was assessed.  Overall, nicotine given via infusion failed to alter significantly the 
colitis severity of the DSS-treated animals.  Only the low dose of 2.5 mg/kg/day exerted a 
significant decrease in the disease activity index on day five compared with the control group 
(Figure 9 A).  However, no significant decrease in the area under the curve of disease activity in 
nicotine-treated mice was seen at both infused doses of the drug (Figure 9 B).  Similarly, nicotine 
treatment failed to significantly reverse the decrease in colon length in the DSS-treated mice 
(Figure 9 C).  However, the low dose of nicotine infusion (2.5 mg/kg/day) showed a significant 
decrease in total histological damage score compared with DSS-treated mice [F(2, 31) = 4.531, 
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p=0.0188] (Figure 9 D). This effect was not observed at the high dose of 25 mg/kg/day of 
nicotine.  In contrast, neither dose of nicotine resulted in lowering the increase in colonic TNF-α 
levels observed for DSS-treated mice [F(3, 46)=16.66, p<0.05] (Table 3). Finally, chronic 
infusion administration of nicotine induced a dose-related manner an increase in the plasma 
levels of nicotine and cotinine in mice (Table 4).  
3.4.4. Effect of cotinine, the main metabolite of nicotine, in the DSS-induced colitis model 
To determine whether cotinine, the principle metabolite of nicotine, possessed anti-
inflammatory effects in the colitis model, DSS-treated animals were subjected to chronic 
cotinine given orally at two different doses (25 and 250 µg/ml).  As shown in Figure 10, cotinine 
administration neither had a significant effect on colitis severity as measured by disease activity 
scores (Figure 10 A & B) nor resulted in a shortening of the colon length (Figure 10 C).  
Cotinine was bioavailable since the plasma levels of the drug and its metabolite (3-OHCotinine) 
(Table 5) were shown to be increased in a dose-related manner after oral administration of the 
drug at 25 and 250 µg/ml.  
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Figure 1 
 
Figure 1. Colonic inflammation was aggravated after DSS exposure to mice in a dose-
related manner.   
(A) Disease activity index (DAI) changes among groups exposed to different doses of DSS (B) 
AUC of DAI for mice in (A). (C) Percentage of body weight change for mice in (A). (D) Mean 
colon length (cm) for the mice in (A).  C57BL/6 mice were given different doses of DSS (1%, 
2.5% and 5%) in the drinking water for 7 days. All clinical signs were assessed on daily basis for 
each mouse and were averaged per day for each group. Results are expressed as mean ± SE, n=6-
8, *p<0.05.  DAI = disease activity index, AUC = area under the curve, Ctrl = water-treated 
animals.  
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Figure 2 
 
 
Figure 2.  Aggravation of inflammatory markers after 7 days of exposure to different doses 
of DSS in mice. 
(A) Colonic MPO activity (midpoint titer/g wet tissue) in groups exposed to different doses of 
DSS (0, 1, 2.5, 5%). (B) Colonic TNF α level (pg/mg protein) for mice in (A). Results are 
expressed as mean ± SE, n=6-8. *p<0.05 Ctrl = water treated group.  Ctrl = water-treated mice, 
MPO = myeloperoxidase activity. 
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Figure 3 
 
Figure 3. Histological scores from colons after 7 days of exposure to water or different 
doses of DSS. 
(A) Loss of epithelium. (B) Crypt damage. (C) Depletion of goblet cells. (D) Infiltration of 
inflammatory cells. (E) Total histological damage score. Histological scores were blindly 
evaluated using H&E stain of the colonic tissue sections after 7 days of water-treated control 
group and DSS-treated animals. Results are expressed as mean ± SE, n=3, *p<0.05. Ctrl = water 
treated group. 
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Figure 4 
   
 
 
Figure 4. Histological analysis of representative colons from mice after 7 days of exposure 
to water or different doses of DSS. 
(A) Appearance of control water-treated control. (B) Appearance of colon treated with 1% DSS. 
(C) Appearance of colon treated with 2.5% DSS. (D) Appearance of colon treated with 5% DSS 
(Haematoxylin-eosin staining of colonic tissue sections, magnification: X40, Scale bar 20µm). 
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Figure 5: Survival rate of C57Bl/6 mice treated with DSS at 2.5 and 5% concentrations for 
7 days then followed 7 days without DSS (recovery phase).  
 
Figure 5. The 5% DSS-treated mice did not survive the recovery phase.  
Mice received DSS (2.5 or 5%) during the acute phase (day 1-7), and replaced with tap drinking 
water during the recovery phase (day 8-14). On day 11: only 33% survived of 5% DSS group, 
while more than 70% survived from mice treated with  2.5% DSS.  
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Figure 6 
 
 
Figure 6. Oral nicotine treatment suppressed the severity of DSS-induced colitis in mice.  
Effects of chronic oral nicotine treatment with various doses (6-100 µg/ml) on (A) the time-
course of DAI. (B) AUC of DAI in mice. (C) Percentage of body weight change. (D) Mean 
colon length (cm). Results are expressed as mean ± SE, n=6-8, *p<0.05 compared to control 
(vehicle-treated mice). Nic = nicotine.  
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Figure 7 
 
Figure 7. Oral nicotine treatment (25 and 100 µg/ml) affects colonic TNF-α levels, 
histological damage score and appearance in DSS-induced colitis. 
(A) Colonic TNF-α levels (pg/mg protein) in the homogenized colonic tissue samples. Results 
are expressed as mean ± SE, n=6-8, *p<0.05 vs. DSS group and #p<0.05 vs Ctrl group. (B) 
Histological colonic damage score in DSS-induced colitis. Representative colon sections at 7 
days after induction of colitis of a control colon (C), DSS-treated mice (D), nicotine (12.5 µg/ml) 
(E), nicotine (25 µg/ml) (F) and nicotine (100 µg/ml) (G). *p<0.05 vs. DSS group, #p<0.05 vs. 
water control group. (Mean ± SE, n=3-5 per group). Nic = nicotine, Ctrl = water-treated group. 
(Haematoxylin-eosin staining of colonic tissue sections, magnification: X40, Scale bar 20µm). 
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Figure 8 
 
 
 
Figure 8. Effect of chronic s.c. nicotine administration on the severity of DSS-induced 
colitis in mice. 
Effects of chronic subcutaneous nicotine treatment (0.1, 0.5 and 2 mg/kg) on (A) the time-course 
of DAI. (B) AUC of DAI. (C) Mean colon length (cm). (D) Histological colonic damage score. 
Results are expressed as mean ± SE, n=6-8, *p<0.05 compared to control (vehicle-treated mice). 
Veh = vehicle, Nic = nicotine, s.c.= subcutaneous. 
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Figure 9 
 
 
 
Figure 9.  Influence of nicotine infusion via mini pump in DSS-treated mice on DAI, 
histological damage and colon length. 
Effects of chronic mini pump infusion nicotine (2.5 and 25 mg/kg/day) on (A) the time-course of 
DAI. (B) AUC of DAI. (C) Mean colon length (cm). (D) Histological colonic damage score. 
Results are expressed as mean ± SEM of n=6-8. *p<0.05 compared to control (vehicle-treated 
mice). Veh = vehicle, Nic = nicotine, MP = mini pump. 
41 
Figure 10 
 
 
Figure 10. Lack of suppression of the severity of colitis by oral cotinine. 
Effects of oral cotinine (25 and 250 µg/ml) on (A) the time-course and (B) AUC of DAI in mice. 
(C) Mean colon length (cm).  Results are expressed as mean ± SEM of n=6-8. *p<0.05 compared 
to control (water-treated mice). 
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Table 1.  Daily fluid volume consumption. 
There was no difference in the daily fluid volume consumption between the water (control) and 
the DSS 2.5% group. 
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Table 2. Effect of subcutaneous nicotine treatment on colonic TNF-α levels in DSS-treated 
mice. Colonic TNF-α levels [pg/mg protein] were expressed as mean ± SE (n = 6-8) after 
treatment with s.c. nicotine (0.1, 0.5 and 2 mg/kg) or vehicle. *p<0.05 compared to water group. 
     
Treatment Water group Vehicle 
Nicotine 
(0.1 mg/kg) 
Nicotine 
(0.5 mg/kg) 
Nicotine 
(2 mg/kg) 
TNF-α levels 
(pg/mg protein) 
20 ± 3.7 78.6 ± 10.7* 82.1 ± 8.3* 68.2 ± 10.6* 89.7 ± 9.7* 
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Table 3. Effect of chronic nicotine infusion on colonic TNF-α levels in DSS-treated mice. 
Colonic TNF-α levels [pg/mg protein] were expressed as mean ± SE (n=6-8) after treatment with 
chronic infusion of nicotine (2.5 and 25 mg/kg/day) or vehicle. *p<0.05 compared to water 
group. The nicotine treatment at dose of 2.5 or 25 mg/kg/day were not significantely different 
compared to the vehicle treated group. 
 
Treatment Water group Vehicle Nicotine 
(2.5 mg/kg/day) 
Nicotine 
(25 mg/kg/day) 
TNF-α levels 
(pg/mg protein) 
20 ± 3.7 73 ± 12.2* 103 ± 8.3* 69.2 ± 9.4* 
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Table 4.  Summary of plasma levels of nicotine and its metabolite cotinine after chronic nicotine 
treatment using s.c. injection, infusion (mini pumps) or oral routes of administration.  Results are 
expressed as mean ± SEM of plasma concentrations in ng/ml. 
 
 
Injection 
(mg/kg) 
Infusion 
(mg/kg/day) 
Oral 
(µg/ml) 
0.5 2 2.5 25 25 100 
Nicotine 
(ng/ml) 
51 ± 
4.7 
163 ± 12 13 ± 
1.5 
97 ± 89 18 ± 7.4 27.5 ± 
12 
Cotinine 
(ng/ml) 
45 ± 
6.5 
97 ± 7 23 ± 5 282 ± 
210 
32 ± 7 240 ± 
61 
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Table 5.  Summary of plasma levels of cotinine after chronic oral cotinine treatment.  Results are 
expressed as mean ± SEM of plasma concentrations in ng/ml. 
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CHAPTER FOUR 
THE ROLE OF α7 NICOTINIC RECEPTORS IN MOUSE DSS COLITIS MODEL 
4.1. Introduction 
   Ulcerative colitis (UC) is an idiopathic, chronic, autoimmune disease characterized by 
mucosal inflammation primarily affects the colon and the rectum (Hanaue, 1996). Curiously, 
various studies have reported that cigarette smoking may have beneficial effects on UC (Harries et 
al., 1982; Boyko et al., 1988; Van Dijk et al., 1995; 1998; Gheorghe et al, 2004; Höie et al., 2007).  
In addition, nicotine patches and enemas have shown positive results on disease symptomology of 
UC in some clinical studies (Srivastava et al., 1991; Guslandi and Tittobello, 1998; Green et. al., 
1997; Sandborn et al., 1997).  In experimental animal models of colitis, nicotine has been shown 
to be effective after oral administration in the treatment of intestinal inflammation (Qiu et al., 1997; 
Eliakim et al., 1998; Sykes et al., 2000; Ghia et al., 2006). Several in vivo and in vitro evidence 
suggest that α7 nicotinic acetylcholine receptors (nAChRs) may mediate the anti-inflammatory 
effects of nicotine (Wang et al., 2003; de Jonge et al., 2005; Ghia et al., 2009).  
Recent studies shown that α7 nAChRs can regulate inflammation primarily through the vagus 
nerve acting as an endogenous “cholinergic (nicotinic) anti-inflammatory pathway”. This system 
ameliorates inflammation by regulating the production of pro-inflammatory cytokines mainly 
through activation of α7 nAChRs on macrophages surface (Borovikova et al., 2000; Tracey et al., 
2001; Wang H et al., 2003, 2004; de Jonge et al., 2005; Ulloa, 2005). Studies reported that vagus 
nerve activation attenuates intestinal inflammation via α7 nAChRs in animal models of 
postoperative ileus and experimental colitis (de Jonge et al., 2005; Ghia et al., 2006; 2007). 
Abdrakhmanova et al., (2010) showed that α7 nAChRs is critical in suppressing hyper excitability 
of inflamed colonic sensory neurons from DSS-colitis mice.  
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In the view of this evidence for an important role of α7 nAChRs in inflammation, it was 
expected that α7 nAChR agonists would ameliorate colonic inflammatory diseases. However, 
Snoek et al., (2010) recently reported that although selective α7 nAChR agonists reduced cytokine 
responses in vitro, they worsened the effects of DSS-induced colitis or were ineffective in those of 
TNBS-induced colitis.  These surprising results prompt us to reevaluate the role of α7 nAChR in 
colonic inflammation in mice.  Many experimental factors such as the dose used, type and receptor 
efficacy of α7 nAChR agonist tested, administration method, disease severity and disease model, 
may explain this unexpected results.  We therefore explored the role of some of these factors on 
the efficacy of α7 nAChR agonists in a mouse colitis model. We first assessed the role of α7 
nAChR in the development of colitis using α7-knockout mice in the DSS model.  We then tested 
the effects of α7 nAChR activation on colitis using selective α7
 
full agonists including PHA-
543613 given systemically (Wishka et al., 2006) and choline given orally (Alkondon et al., 1997; 
Albuquerque et al., 1998; Fayuk and Yakel, 2004).  We also evaluated the effects of PNU-120596, 
a type II α7
 
nAChRs positive allosteric modulator (PAM) in the DSS model.  PAMs, in principle, 
can enhance endogenous α7 nAChR functions without altering the temporal integrity of 
neurotransmission or interacting directly with the α7 nAChR binding site.  This property would 
allow enhancing a potential endogenous α7-mediated anti-inflammatory tone activated in the 
colitis model.  The use of PNU-120596 would also help investigating the role of receptor 
desensitization since type II PAMs cause a dramatic slowing of receptor desensitization (Hurst et 
al., 2005; Bertrand and Gopalakrishnan, 2007; Sitzia et al., 2011).  
4.2. Materials and Methods  
For more details see Chapter 2.  
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4.2.1. Study 1: DSS-induced colitis model in α7 KO and WT nAChR mice.  
DSS 2.5% (wt/vol) was added to the drinking water of wild-type and α7 KO nAChR mice for 7 
days. On day 8, DSS was replaced with normal drinking water. Controls were all age- and time-
matched and consisted of mice that received regular tap drinking water only for the 
corresponding number of days. The experimenter was blinded to the mouse genotype.  
4.2.2. Study 2: Effect of chronic PHA-543613 and choline treatment in DSS-induced colitis 
model. Male C57BL/6J mice pre-treated with either PHA-543613 (2, 8, and 20 mg/kg s.c. twice 
daily) or vehicle. A separate group of mice were treated with oral administration of choline (10, 
40, and 80 µg/ml) in the drinking water 3 days before adding the DSS, and for 7 days along with 
the induction of colitis with DSS 2.5%. On day 8, DSS was replaced with normal drinking water. 
4.2.3. Study 3: Effect of chronic PNU-120596 treatment in DSS-induced colitis model. Male 
C57BL/6J mice pre-treated with either PNU-120596 (1, 3, and 6 mg/kg i.p. once daily), or 
vehicle, started 3 days pre-DSS treatment and for 7 days along with the induction of colitis with 
DSS 2.5%. On day 8, DSS was replaced with normal drinking water. 
4.3. Results 
4.3.1.  DSS-induced colitis in α7 KO mice 
   In this experiment we assessed the progress of the clinical parameters during the DSS 
treatment in mice lacking α7 nicotinic receptors and their littermates’ wild type. α7 KO mice 
treated with 2.5% DSS displayed a significant increase in inflammation as expressed in the disease 
activity index value starting from day 5 till day 8 of the experiment [t(8)=2.85, p=0.0213] (Figure 
11 A) and in the area under the curve [t(9)=5.788, p=0.003] (Figure 11 B) compared with the WT 
DSS-treated mice. Both α7 KO and WT DSS-treated mice displayed a significant loss of body 
weight, especially α7 KO from the control water-treated mice only (Figure 11 C). The decrease in 
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the colon length was significantly different between α7 KO and WT DSS-treated mice, even more 
significant in α7 KO against water-treated control group [F(2, 19)= 117.6, p<0.0001] (Figure 11 
D).   To assess the extent of inflammation in the colon, we evaluated the histological damage score 
and TNF-α colonic levels. The representative of colon histological damage changes were 
expressed as the total histological change score (Figure 12 A). α7 KO mice treated with DSS 
showed a significant increase in colonic total histological damage score versus the WT DSS and 
the water-treated control group, [F(2, 47) = 39.24, p<0.001] (Figure 12 A). The histological 
appearance of the colon after 7 days of DSS treatment in the WT mice was characterized by 
multifocal changes in the crypts and some areas showed focal lesions, depletion of goblet cells and 
inflammatory cell infiltrates, including neutrophils and lymphocytes; however, these changes with 
epithelial destruction were seen more shortening of the crypts, inflammatory cell infiltrates, 
extensive ulceration and the inflammation was mainly in the mucosa, and submucosal in colons 
from the α7 KO DSS-treated mice (Figure 12 B).  
Next, we measured colonic TNF-α level to observe the influence of α7 nicotinic receptor 
subunit on colonic inflammation in DSS-induced colitis. In the line with the worsen in the clinical 
parameters and histological damage score in α7 KO DSS-treated mice. The α7 KO DSS-mice 
showed significant elevated colonic TNF-α levels, approximately 1 fold increased compared to 
WT DSS-treated mice [F(2, 39) = 32.64, p<0.001] (Figure 12 C).   
4.3.2. Effect of α7 nAChR agonists and PAM in DSS colitis model: 
4.3.2.1. Effect of PHA-543613 on DSS-induced colitis model in mice 
Treatment with twice daily of s.c. PHA-543613, a selective α7 nAChRs agonist.  At low dose of 
2 mg/kg does not affect either clinical parameters of colitis severity (Figure 13 A and B) or the 
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colon length (Figure 13 C); however a higher dose of 8 mg/kg significantly decreased disease 
activity index scores on day 6, 7, and 8 compared to DSS-treated group [F(2, 16) = 4.051, 
p=0.0377] (Figure 13 A), and in the area under the curve value as well [F(3,30) = 5.403, 
p=0.0043] (Figure 13 B). In addition, at that dose, PHA-543613 was able to reverse the 
shortening of the colon length of DSS-treated group [F(3, 19) = 7.495, p=0.0017] (Figure 13 C). 
As the dose increased to 20 mg/kg, PHA-543613 worsen the disease activity and shortened the 
colon length in the DSS-treated mice. PHA-543613 at 8 and 20 mg/kg did not reduce the 
increase in colonic TNF-α levels seen with DSS-treated mice (Figure 13 D).  
In this experiment we also assessed the effects of PHA-543613 on the colonic histological 
damage in the DSS-treated mice. PHA-543613 at both doses (8 and 20 mg/kg) has no effect on 
the total histological damage score induced by DSS treatment (Figure 14 A).  Figure 14 B, 
showed histological appearance of the colon sections with H & E stain after PHA-543613 
treatment in DSS-treated mice. The DSS-treated animals were showed ulceration and destruction 
of the mucosal architecture with inflammatory cells infiltrate of polymorphonuclear leukocytes 
including numbers of macrophages and lymphocytes were the inflammation was mainly in the 
mucosa, and more shortening of the crypts (Figure 14 B, b). However, PHA-543613 treatment at 
8 and 20 mg/kg had no effect on the total histological damage score compared with vehicle DSS-
treated animals, at high dose of 20 mg/kg, PHA-543613 produced extensive epithelial and 
architecture destruction mainly in the mucosa and submucosa with inflammatory infiltrates 
(Figure 14 B, c and d).  
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4.3.2.2. Effect of Choline on DSS-induced colitis model in mice 
We then tested the effect of another α7 nAChRs agonist, choline given in the drinking water.  As 
seen in Figure 15 A & B, low dose of oral choline treatment (10 µg/ml) has no significant effect 
on the severity of clinical parameters of DSS-induced colitis model (Figure 15 A & B) or the 
shortening of the colon length (Figure 15 C). However, choline at higher dose of 40 µg/ml, 
significantly decreased disease activity index values on day 7 and 8 compared to the DSS-treated 
group [F(3, 24) = 4.818, p=0.0092] (Figure 15 A), and in the area under the curve as well [F(3, 
23) = 3.15, p=0.044] (Figure 15 B). In addition, that dose was able to reverse the shortening of 
the colon length of DSS-treated group [F(3, 20) = 7.812, p=0.0012]. As the dose increased to 80 
µg/ml, the protective effect of choline on disease activity and colon length disappeared in the 
DSS-treated mice (Figure 15 A, B & C).  Both doses (40 and 80 ug/ml) of choline did not reduce 
the increase in colonic TNF-α levels seen with DSS-treated mice (Figure 15 D). 
Interestingly, choline treatment at 40 and 80 µg/ml significantly decreased the total 
histological damage score of the colon compared to the vehicle DSS-treated group [F(2, 97) = 
11.43, p<0.001] (Figure 16 A).  As seen in Figure 16 B, the DSS-treated animals showed 
destruction of the mucosa, and extensive inflammatory cell infiltrates (b) as compared to the 
water-control (a) group. Choline at 40 and 80 µg/ml reversed the histological damage and 
normalized the epithelial architecture of the colon (Figure 16 B; c and d, respectively). 
4.3.2.3. Effect of α7 nAChR positive allosteric modulator (PAM) in DSS colitis model: 
As with PHA-543613 and choline, low dose of PNU-120596 treatment (1 mg/kg, i.p.) did not 
reverse the DSS-induced colitis as measured by the disease activity index scores (Figure 17 A & 
B). However, at dose of 3 mg/kg, PNU-120596 significantly decreased disease activity index 
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scores on day 5, 6, 7 and 8 compared to DSS-treated group [F(3, 24) = 8.01, p=0.0007] (Figure 
17 A). In addition, at this dose, it significantly reduced the area under the curve of disease 
activity index score compared with vehicle DSS-treated mice [F(3, 18) = 3.341, p=0.0425] 
(Figure 17 B). As the higher dose of 6 mg/kg, the protective effect of PNU-120596 on disease 
activity disappeared in the DSS-treated mice (Figure 17 A & B).  
   None of the PNU-120596 doses tested did reduce the increase in colonic TNF-α levels seen 
with DSS-treated mice (Figure 17 D).  However, PNU-120596 treatment at 3 mg/kg significantly 
decreased the total histological damage score in DSS-treated mice [F(2, 67) = 3.88, p=0.0254] 
(Figure 18 A). At a higher dose of 6 mg/kg, PNU 120596’s effects on the total histological score 
failed to reach statistical significance.  As shown in Figure 18 B, the extensive ulceration of the 
mucosa and increase in inflammatory cell infiltrates induced by DSS was reversed by PNU- 
120596 treatment (c). 
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Figure 11 
 
Figure 11. Colonic inflammation was aggravated after DSS exposure in α7-deficient mice. 
(A) Clinical evaluation of disease activity index of α7 wild type and Knock-out mice treated with 
2.5% DSS in time-course manner. The DAI values were computed as described in detail in 
Methods. (B) Area under the curve of DAI. (C) Percentage of body weight change during DSS 
treatment period. (D) Colon length (cm) after DSS treatment. All clinical signs were assessed on 
daily basis for each mouse and were averaged per day for each group. Results are expressed as 
mean ± SE, n=6-8, *p<0.05.  DAI = disease activity index, AUC = area under the curve, Ctrl = 
water-treated animals.  
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Figure 12 
 
Figure 12. Histopathologic changes in colonic tissues and colonic TNF α level following 1 
week of dextran sulphate sodium administration in α7 deficient mice.  
(A) Histological damage score significantly increased in colon from α7 KO mice. (B) The histological 
appearance of the colon after DSS treatment in α7 WT and KO mice. Some epithelial architectural 
destruction with minimal submucosal inflammation in colonic tissue of wild type mice. In the α7 KO 
mice colon, shown extensive mucosal and submucosal injury with inflammatory infiltrate in the mucosa 
and submucosa. Histology alteration in mucosal tissue assessed using haematoxylin-eosin staining, (H&E 
staining; magnification X20). (Mean ± SE, n=6-8, p<0.05). (C) TNF α level [pg/mg protein], an acute 
inflammatory marker, was measured by enzyme-linked immunosorbent assay (ELISA). DSS induced 
colitis significantly increased the TNF α level in the homogenized colonic tissue especially in α7 deficient 
mice samples. (Mean ± SE, n=3 per group, p<0.05). Ctrl = water-treated animals.  
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Figure 13 
 
 
Figure 13. Effect of PHA-543613 on DAI and inflammatory markers in C57Bl/6 mice with 
DSS colitis. Effect of chronic PHA-543613 treatment on (A) the time-course of Disease activity 
index. (B) Area under the curve of disease activity index in mice. (C) Mean colon length (cm). 
(D) Colonic TNF-α levels (pg/mg protein) in the homogenized colonic tissue samples. Results 
are expressed as mean ± SE, n=6-8, *p<0.05 compared to Veh. #p<0.05 vs. Ctrl in (C) and vs. 
Veh in (D). Ctrl = water-treated animals, Veh = vehicle DSS-treated mice, s.c.= subcutaneous.  
 
57 
Figure 14 
 
Figure 14. Histological analysis of representative colons from C57Bl/6 mice after 7 days of 
exposure to water, vehicle, or PHA-543613 treatment. 
(A) The total histological colon damage score after PHA-543613 in C57Bl/6 mice. (B) 
Appearance of a control colon (a), DSS-treated mice (b), and colon from PHA-543613 
treatments (8 and 20 mg/kg; c and d respectivily) in DSS-treated mice. (Haematoxylin-eosin 
staining of colonic tissue sections, magnification: X40, Scale bar 20µm). Results are expressed 
as mean ± SE, n=3, #p<0.05 vs. Ctrl. Ctrl = water-treated animals, Veh = vehicle DSS-treated 
mice.  
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Figure 15 
 
Figure 15. Chronic oral choline treatment suppressed the severity of DSS-induced colitis in 
mice.  
Effect of oral choline treatment on (A) the time-course of disease activity index, (B) Area under 
the curve of disease activity index, (C) Mean of colon length (cm). (D) Colonic TNF-α levels 
[pg/mg protein] in the homogenized colonic tissue samples. Results are expressed as mean ± SE, 
n=6-8, *p<0.05 vs. DSS group and #p<0.05 vs Ctrl group. Ctrl = water-treated animals, Veh = 
vehicle DSS-treated mice, po = oral.  
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Figure 16 
 
Figure 16. Histological analysis of representative colons from C57Bl/6 mice after 7 days of 
exposure to water, vehicle, or choline treatment in C57Bl/6 mice with DSS colitis. 
(A) The total histological colon damage score after oral choline treatment in mice. (B) 
Histological appearance of a control colon (a), DSS-treated mice (b), oral choline (40 µg/mL) in 
DSS-treated mice (c), oral choline  (80 µg/mL) treatment in DSS-treated mice (d). 
(Haematoxylin-eosin staining of colonic tissue sections, magnification: X20). Results are 
expressed as mean ± SE, n=3, #p<0.05 vs. Ctrl. Ctrl = water-treated animals, Veh = vehicle 
DSS-treated mice. 
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Figure 17 
 
Figure 17. Effect of PNU-120596 on DAI, colonic TNF-α level and colon length in C57Bl/6 
mice with DSS colitis. 
Effect of PNU-120596 treatment on (A) the time-course of disease activity index in DSS-treated 
mice. (B) Area under the curve of disease activity index, (C) Mean of colon length (cm). (D) 
Colonic TNF α level [pg/mg protein] in the homogenized colonic tissue samples. Results are 
expressed as mean ± SE, n=6-8, *p<0.05 vs. Veh. #p<0.05 vs. Ctrl. Ctrl = water-treated animals, 
Veh = vehicle DSS-treated mice.  
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Figure 18 
 
 
Figure 18. Influence of PNU-120596 on histological damage score in C57Bl/6 mice with DSS 
colitis (A) The total histological colon damage score after chronic PNU-120596 treatment in 
DSS-treated mice. (B) The histological appearance of normal colon (a), vehicle DSS-treated 
mice (b), PNU-120596 (3 mg/kg) in DSS-treated mice (c), PNU-120596 treatment (6 mg/kg) in 
DSS-treated mice (d). Results are expressed as mean ± SE, n=3 per group, p<0.05. 
(Haematoxylin-eosin staining of colonic tissue sections, magnification: X40, Scale bar 20µm). 
#p<0.05 vs. Ctrl group, and *p<0.05 vs. Veh group.  Ctrl = water-treated animals, Veh = vehicle 
DSS-treated mice. 
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CHAPTER FIVE 
Role of non-α7 Nicotinic Receptors in Experimental Colitis  
5.1. Overview  
      Nicotine exerts its effect through acting on various subtypes of nicotinic receptors in multiple 
sites, centrally and peripherally. As described before in Chapter 1, these nicotinic receptors are 
express in the CNS, PNS, and non-neuronal tissues, such as immune cells. Human lymphocytes 
express mRNA for α3, α4, α5, and β4 nAChR subunits (Hiemke et al., 1996; Mihovilovic et al., 
1998; Mihovilovic and Roses, 1991, 1993). Human mononuclear leukocytes express mRNAs 
encoding α2 and α5 nicotinic subunits (Sato et al., 1999). α9 and α10 nicotinic subunits have 
restricted anatomical tissue distribution profile among the nicotinic receptors. While they have 
not been detected in the brain and spinal cord (Elgoyhen et al., 2001; Sgard et al., 2002), they are 
expressed in human T cells, blood lymphocytes, monocytes, macrophages (Lustig et al., 2001, 
Peng et al., 2004; Galvis et al., 2006; Kawashim et al., 2007), and in dorsal root ganglion (DRG) 
neurons (Lips et al., 2002).  
   Nicotinic receptor subunits are also expressed in the ENS. For example, mRNA for α3, α5, β2 
and β4 have been detected in the myenteric plexus of large intestine and α3, α5 and β4 
expression in some ganglia of the submucosal plexus of large intestine in rat; however, there was 
no evidence for expression of α4, α6 and β3 mRNA in these tissues (Garza et al., 2009). 
Furthermore, nicotinic receptors have been identified in colonic epithelial HT29 cells, including 
α3, α5 nAChR subunits (Summers et al., 2003).  
The distribution pattern of these various non-α7 nicotinic receptors suggests a possible role for 
them in the process of colitis.  
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One promising target is α9 and α10 nicotinic acetylcholine receptor especially after the 
discovery of a novel selective α9α10 conotoxin antagonist. α-Conotoxins are small neurotoxic 
disulfide rich peptides derived from the marine cone snails venom of Conus species (Terlau and 
Olivera, 2004). Alpha-conotoxin RgIA (α-RgIA) is one of three reported α-conotoxins that block 
the α9α10 nicotinic receptors and is the most potent α9α10 nAChR subtypes antagonist with an 
IC50  5.2 nM in Xenopus oocytes (Ellison et al., 2006; Vincler et al., 2006; Nevin et al., 2007). 
Interestingly, nicotine acts as an antagonist of rats α9 and α9α10 nAChRs (Elgoyhen et al., 1994, 
2001; Sgard et al., 2002; Verbitsky et al., 2000). Recent studies have provided evidence that 
administration of α9α10 selective α-conotoxin antagonists produce antinociceptive and anti-
inflammatory effects in neuropathic and tonic inflammatory pain animal models (McIntosh et al., 
2009; Vincler et al., 2006; Vincler and McIntosh, 2007). Immune cells seem to mediate the anti-
inflammatory effect of α9α10 nAChRs antagonist. Indeed, blockade of α9α10 nAChRs in 
chronic constriction injury animals showed a decrease of lymphocytes and macrophages at the 
site of nerve injury (Vincler and McIntosh, 2007; Vincler et al., 2006). The activation of the 
functional cholinergic receptors in leukocytes might mediate the nicotinic anti-inflammatory 
pathway through these immune cells. While the function of α9α10 nAChRs in the auditory 
system has been well characterized (Elgoyhen AB et al., 2001), little is known regarding the 
function of α9α10 nAChRs in immune cells and inflammation. The α9α10 nAChR selective 
antagonist, α-conotoxin RgIA, enabled us to explore the role for α9* nAChRs in animal DSS 
colitis model.  
Here, because of the expression and distribution of non-α7 nicotinic receptors in peripheral 
nervous system and non-neuronal tissues; we examined the role of α5 and β2 nAChR subunits 
using α5- and β2-deficient nicotinic subunits KO mice using DSS-induced colitis model.  In 
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addition, we explored the role of α9 nAChR subtypes by testing the effect of α-conotoxin RgIA, 
a α9α10 nAChR selective antagonist, in C57Bl/6 DSS-treated mice.  
5.2. Materials and Methods.  
See Chapter 2 for more details.  
5.2.1. Study: Role of non-α7 nicotinic receptor (α5, β2, and α9) subtypes in DSS-induced 
colitis model in mice.  We induced colitis in α5 and β2 nicotinic receptor KO mice, and their 
littermates wild-type nicotinic receptor male adult mice were given DSS solution freely in the 
drinking water for 7 consecutive days after which tap water was given on the 8th day. α-RgIA 
was administered s.c. once daily for 10 days in C57Bl/6 male mice, started 3 days pre-DSS and 7 
days with DSS treatment. α-RgIA doses range (0.02, 0.1, 0.2 mg/kg). We measured the clinical 
parameters every day over the time-course of the study and the colon length at the end of the 
study.  
5.3. Results: There were no significant differences in the disease activity scores and the area 
under the curve of disease activity seen between the β2, and α5 deficient mice and their 
littermates WT DSS-mice (Figure 19 A-D). In addition, colon shortening was not affected in β2, 
and α5 KO subunits DSS-treated mice (Figure 19 E and F). 
   Repeated subcutaneous treatment with a low dose of 0.02 mg/kg of α-RgIA once daily 
produced a significant decrease of disease activity score on day 8 and in the area under the curve 
(Figure 20 A & B). However, this effect was lost at higher doses of α-RgIA  (0.1 and 0.2 mg/kg). 
Both high doses had no effect on the disease activity score. α-RgIA doses of 0.02 and 0.1 mg/kg 
in DSS-treated mice did not have a significant loss of body weight compared with the vehicle 
DSS-treated mice (Figure 20 C); however, at higher dose of α-RgIA (0.2 mg/kg) mice displayed 
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a significant percentage of body weight loss from the DSS-treated mice on day 8. α-RgIA at any 
of the tested doses had no effect on the shortening of the colon length of DSS-treated mice 
(Figure 20 D). 
  Chronic subcutaneous α-RgIA administration at dose of 0.02 mg/kg had no effect on reducing 
the total histological colonic damage score; interestingly, at higher dose of 0.2 mg/kg, α-RgIA 
showed a significant decrease in total histological damage score in a dose-dependent manner 
(Figure 21 A). At all tested doses, α-RgIA did not reduce the colonic TNF-α pro-inflammatory 
cytokine levels; interestingly, at low dose of 0.02 mg/kg, RgIA did not increased or decreased 
TNF-α levels (Figure 21 B). 
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Figure 19 
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Figure 19. Clinical evaluation of non-α7 nicotinic receptor subtypes, particularly α5 and β2 
in DSS-induce colitis model in mice. 
(A, C) The time-course of Disease activity index (DAI). (B, D) Area under the curve of DAI. (E, 
F) Colon length (cm). All clinical signs were assessed on daily basis for each mouse and were 
averaged per day for each group. Results are expressed as mean ± SE, n=6-8, *p<0.05.  DAI = 
disease activity index, AUC = area under the curve.  
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Figure 20 
 
Figure 20. Effect of repeated subcutaneous α-RgIA administration on the severity of DSS-
treated C57BL/6J mice  
Effects of chronic subcutaneous α-RgIA treatment (0.02, 0.1 and 0.2 mg/kg) on (A) the time-
course of DAI. (B) AUC of DAI. (C) loss of body weight, and (D) Mean colon length (cm). 
Results are expressed as mean ± SE, n=6-8, *p<0.05 vs. Veh group.  Ctrl = water-treated animals, 
Veh = vehicle DSS-treated mice. 
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Figure 21 
 
 
Figure 21.  Effect of repeated subcutaneous α-RgIA treatment in DSS-treated C57BL/6J 
mice on histological damage, and inflammatory marker. 
(A) Histological colonic damage score in DSS-induced colitis, (B) Colonic TNF-α levels (pg/mg 
protein) in the homogenized colonic tissue samples.  Results are expressed as mean ± SE, n=6-8, 
#p<0.05 vs. Ctrl group, and *p<0.05 vs. Veh group.  Ctrl = water-treated animals, Veh = vehicle 
DSS-treated mice. 
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CHAPTER SIX 
General discussion, summary and future studies. 
   The identification of nicotinic acetylcholine receptors (nAChRs), their distributions, structures, 
and functions increased understanding of the complexity of these receptors. The expression of 
nAChRs in the enteric nervous system (ENS) and immune cells suggest that they may play an 
important role in the gut regulation and inflammatory processess. Several clinical trials have 
tested nicotine efficacy in UC patients in various pharmaceutical formulations, including gum, 
transdermal patches, enemas (Perera et al., 1984; Lashner et al., 1990; Srivastava et al., 1991; 
Guslandi and Tittobello, 1994, 1996; Pullan et al., 1994; Thomas et al., 1995, 1996; Sandborn et 
al., 1997; Green et al., 1997; Ingram et al., 2005). It has been thought that nicotine alleviates UC 
through acting on nicotinic receptors in the gut immune cells (Thomas et. al., 2005). The 
expression of nAChRs on lymphocytes, such as T-cells play a role in immunocytes 
differentiation, development, and function (Fujii et al., 2008). In addition, an earlier study 
showed that CD4 T cells have a role in experimental animal model of colitis (Elson et al., 1998). 
  Nicotine may have possible effects on various immunocytes of the immune system. In fact, 
immune cells express different nAChR subtypes. For example, α7 nicotinic receptors are present 
in intestinal lamina propria lymphocytes (Kikuchi et al., 2008) which may have important role in 
the pathogenesis and signaling pathway of intestinal inflammation. 
6.1. DSS-induced colitis model dose-response curve in mice 
    Previous studies used different concentrations of DSS solution in animals (Ahmad et. al., 2000; 
Araki et. al., 2000; Egger et. al., 2000). Furthermore, in the present study we demonstrated that 
as the DSS concentration increased, the severity of disease increased, including bloody diarrhea, 
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rectal irritation, body weight loss, and colonic histolopathology of mucosal injury (Egger et al., 
2000). In the present study, we showed that 7 days of 2.5% DSS administration in the drinking 
water resulted in an acute inflammation of the colon with low rate of mortality. We showed all of 
the clinical signs of disease activity manifested by the loss of body weight, bloody diarrhea, 
rectal irritation, shortening of the colon, ulceration in the colonic mucosa which allows the 
infiltration of inflammatory cells into the lamina propria, including neutrophils and lymphocytes. 
The migration of neutrophils into the mucosa and the epithelial surface cause intestinal 
inflammation. To further examine the extent of the inflammation in the colon, we measured two 
inflammatory markers, colonic MPO activity and TNF α level. MPO is an enzyme in neutrophils 
used as a marker of inflammation and an index of neutrophil infiltration (Bradley et al., 1982). A 
reduction in the activity of this enzyme can be considered as an anti-inflammatory activity of the 
given treatment. TNF α is an early pro-inflammatory mediator, and plays a critical pathological 
role in the colonic inflammation. Both inflammatory markers were significantly increased after 7 
days of DSS treatment in a dose-related fashion.  
6.2. Influence of nicotinic dose and route of administration in mouse DSS colitis model 
   One of the objectives of this study was to determine the pharmacology of protective 
effects of nicotine in the DSS-induced colitis mouse model.  In addition, we assessed whether 
cotinine, the main metabolite of nicotine, was effective in this model.   The results suggest that 
low doses of nicotine delivered orally, but not cotinine, are most effective in rendering a 
protective effect in the mouse DSS colitis model.  Our results demonstrated that the dose and 
route of administration play a pivotal role in nicotine’s in vivo anti-inflammatory efficacy in the 
DSS model of colitis.  While the continuous infusion of a low dose of nicotine (2.5 mg/kg/day) 
through mini pumps resulted in a modest and short improvement of clinical signs and 
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histological damage, the effect was not observed at the higher dose of nicotine (25 mg/kg/day).  
Similarly, chronic s.c. injection of low dose of nicotine at 0.1 mg/kg resulted slightly  
improvement in clinical signs; however failed to reach statistical significant and at 0.5 mg/kg 
resulted in a reversal of the shortening in colonic length.  This effect was not observed at the 
high dose of 2 mg/kg of nicotine.  However, nicotine treatment in both routes of administration 
did not effect a reversal in DSS-induced increase in colonic TNF-α levels.  In contrast, oral 
nicotine treatment attenuated dose-dependently DSS-induced colitis.  The low doses of nicotine 
(12.5-50 µg/ml) were shown to exert a protective effect; they resulted in a reduction in DAI and 
histological architectural damage and in a reduction in colonic TNF-α levels.  However, the 
protective effects of nicotine in the DSS colitis model dissipated at the high dose of 100 µg/ml.  
Interestingly, nicotine plasma levels increased only 1.5-fold between the doses of 25 and 100 
µg/ml (Table 4) suggesting a narrow concentration-effect profile for oral nicotine in the DSS 
model.  Curiously, oral nicotine treatment at any of the doses tested failed to reverse significantly 
the shortening in the colon length in the DSS-treated group.  
The biphasic effect of chronic nicotine treatment on clinical parameters in DSS-induced 
colitis in mice was not unexpected.  The low doses of oral nicotine (12.5–25 µg/ml) were shown 
to be protective while the higher doses were not.  The low doses administered in drinking water 
resulted in a reduction of DAI, histology architectural damage and colonic TNF-α levels, 
whereas the high dose (100 µg/ml) resulted in an exacerbation of DSS colitis including the DAI 
and the AUC. Exacerbation of DAI at high doses of nicotine was not observed in s.c. or 
minipump nicotine-treated animals, suggesting a differential effect of nicotine dose and delivery 
on colonic inflammation.  The results indicative of protective effects of low dose of nicotine in 
the drinking water were similar to those reported previously in various experimental colitis 
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models in rats and mice (Qiu et al., 1997; Eliakim et al., 1998; 2001; Sykes et al., 2000; Ghia et 
al., 2006).  Qiu et al., (1997) demonstrated that nicotine treatment at a dose of 5 ug/ml in the 
drinking water in DNBS-treated rats resulted in a significant decrease in the intestinal 
inflammation; however, the inflammation was shown to increase at a dose of 50 ug/ml.  
Similarly, Eliakim et al., (1998) and Sykes et al., (2000) reported that nicotine had a dual effect 
on colitis in mice with low doses of nicotine being more effective at reducing the inflammation 
than higher doses. This dual anti-inflammatory effect of nicotine in the form of an “inverted-U,” 
has been described previously in behavioral effects of nicotine (Picciotto, 2003).  
Overall, our results suggest that the route of administration of nicotine is an important 
factor to consider in the treatment of colitis.  The lack of a clear anti-inflammatory effect of 
nicotine after s.c. and minipump infusion in the DSS model, could explain some of the 
inconsistent results that have been reported previously in rodent (Snoek et al., 2010) and human 
studies.  Notably, the marginal effects observed after infusion of a constant dose of nicotine 
through minipumps is consistent with lack of effects of nicotine using transdermal patches in 
some UC studies (Pullan et al., 1994; Cosnes et al., 2004; McGilligan et al., 2007), suggesting 
that a route of administration that mimics nicotine intake profile seen in smokers, could result in 
an increase in the efficacy of treatment.  Indeed, these and other (Eliakim et al., 1998; 2001; 
2002; Sykes et al., 2000; Ghia et. al., 2006) results suggest that administering nicotine orally is a 
very efficacious route in reversing colitis in rodent models.  This outcome is consistent with that 
obtained through UC studies using rectal administration of nicotine.  A possible explanation for 
these results is that nicotine targets and affects the colon locally when administered orally with 
marginal therapeutic index.  Other possible mechanisms of nicotine effects have been proposed. 
For example, the beneficial effects of oral nicotine treatment could be due to nicotine exerting 
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anti-inflammatory effects partially through changes in colonic TNF-α levels or through inhibition 
of release of TNF-α and other pro-inflammatory cytokines from cytokine-producing cells. In the 
mouse colitis model used in this study, colonic TNF-α levels were reduced significantly by the 
low dose of oral nicotine treatment, which is most likely mediated via suppression of pro-
inflammatory cytokine release from macrophages and other cytokine-releasing immune cells as 
part of the initial innate immune response to DSS.  
Although the colon may be an important site of action for nicotine following oral 
administration, the drug likely acts on many peripheral and central inflammatory pathways.  
Indeed, nicotine is absorbed in the small intestine with low bioavailability (up to 45%) because 
of a hepatic first pass effect (Benowitz et al., 1991; Compton et al., 1997; Zins et al., 1997).  In 
the present study, oral administration of nicotine in the drinking water yielded measurable levels 
of nicotine in the plasma.  For example, a plasma nicotine concentration of 18 ng/ml was found 
after an oral administration of an active dose of 25 µg/ml of the drug.   
It has been proposed that some nicotine metabolites contribute to the beneficial effect of 
nicotine in UC patients, since the majority of nicotine is converted to cotinine (about 80%) 
through the cotinine pathway and is present in smokers in blood at much higher concentrations 
(about 250 to 300 ng/ml) than nicotine (Benowitz et al., 1983; Gori and Lynch, 1985; Benowitz 
and Jacob, 1994).  In the present study, this hypothesis was tested by administering cotinine 
directly in the drinking water.  The results show that oral cotinine administration has no 
protective effect in the mouse colitis model based on clinical parameters or measurement of 
colon length. Plasma concentrations after 10 days of cotinine oral administration of 25 and 250 
µg/ml were 90 and 1336 ng/ml, respectively.  These plasma levels cover well and above the 
concentration range of cotinine found after nicotine administration protocols used in our various 
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studies. The lack of effect of cotinine suggests that this major metabolite does not mediate the 
anti-inflammatory effects of nicotine reported in rodents and human studies.  However, other 
metabolites such as nornicotine, which is a component in tobacco as well as a minor systemic 
metabolite of nicotine and is a nAChRs agonist (Papke et al. 2007), cannot be ruled out of the 
effects of nicotine.   
     Overall, our results with nicotine suggest that the protective effects of the drug are influenced 
by the route of administration and the dose of exposure.  While nicotine is a non-selective 
agonist at the various nAChRs subtypes, several in vitro and in vivo evidence suggest that α7 
nAChRs subtypes mediate its anti-inflammatory effects.  In addition, it has been reported that α7 
nicotinic receptor subunit may play an important role in experimental colitis (Ghia et al., 2006; 
2007) and its effect mediated through activation of the cholinergic anti-inflammatory pathway 
(Wang et al., 2003; de Jonge et al., 2005; Kelso et al., 2006; Hamano et al., 2006).   We therefore 
investigated the role of α7 nAChRs in the development of experimental colitis in mice. 
6.3. Influence α7 nicotinic receptors in mouse DSS colitis model 
     The results presented in our study show that mice lacking α7 nicotinic receptor develop a 
marked increase in clinical colitis scores and colonic inflammation markers in the mouse DSS 
model.  In contrast, α7 nAChRs agonists and PAM reduced the severity of the disease at a narrow 
range of doses.  Taken together, these results strongly suggest an important role for a cholinergic 
anti-inflammatory pathway in the development of colitis, which at least in part is mediated by α7 
nAChRs.   
      In the present study, we showed that α7 KO mice treated with 2.5% DSS have a significant 
increase in the disease activity index scores and decrease in the colon length; however, there were 
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no body weight difference between the α7 deficient and WT mice treated with DSS.  This was 
accompanied by an increase in colonic histological damage and elevated pro-inflammatory 
cytokine levels of TNF-α.  TNF-α is an early pro-inflammatory mediator that plays an important 
role in immuno-inflammatory responses and in the pathogenesis of UC (Yokota et al., 1988; and 
Anand and Adya, 1999).  These results are consistent with recent data from various animal models 
of inflammation that point towards the α7 nAChR subtypes as an important player in cholinergic 
modulation of inflammation (Wang et al., 2003; Wang et al 2004; Ulloa, 2005; de Jonge et al., 
2005; van Maanen et al., 2010).  They are also in agreement with Ghia et al., (2009) study that 
showed that α7-deficient mice treated with DSS for 5 days showed an exaggeration of the colitis 
severity with an increase in the colonic inflammation including histological damage score, pro-
inflammatory cytokine, IL-1β colonic levels and MPO activity compared with the WT mice.  In 
addition, nicotine pretreatment counteracted the colitis inflammation in WT and lacks its effect in 
the α7 KO mice.  
     In line with our α7 KO observations, α7 nAChR agonists and PAM (PHA-543613, PNU-
120596 and choline) were effective in reversing the clinical parameters of colitis and shortening of 
the colon induced by DSS in mice; however, PAM did not reverse the shortening of the colon 
length. This reduction was less pronounced with histopathology damage scores and levels of 
colonic TNF-α.  The antinflammatory effects of all three α7 nAChR ligands occur at narrow dose 
ranges with U-shape dose-response relationships, with choline being relatively the most effective 
in that regard. Choline is an essential nutrient, a cell membrane constituent, a precursor in the 
biosynthesis of acetylcholine, and a selective natural full α7 nAChR agonist (Papke et al., 1996 
and Alkondon et al., 1997). Interestingly, choline level is low in the colonic tissues from UC 
patients (Bjerrum et al., 2010). When choline administered orally, it is absorbed in the intestine 
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(Lekim and Betzing, 1976; Pelech and Vance, 1984; Tian et al., 2012) and its uptake is localized 
in the neural part of the intact intestine of the guinea pig small intestine (Snyder et al., 1973; Pert 
and Snyder, 1974). Recently, the anti-inflammatory efficacy of choline in murine endotoxemia 
and sepsis and its modulation of TNF release require α7 nAChR-mediated signaling (Parrish et al., 
2008). Possibly, the lack of choline protective effect could contribute, at least in part in the 
development of colitis in active UC. 
      Our data with PNU-120596, a type II α7 nAChR PAM, suggest the presence of a pro-
“anticolitis” endogenous tone mediated by α7 nAChRs. Generally speaking, PAMs are compounds 
that facilitate endogenous neurotransmission and/or enhance the efficacy and potency of agonists 
without directly stimulating the agonist binding sites. PNU-120596 may be acting in the DSS test 
through the enhancement of sub-threshold concentrations of endogenous α7 agonists, choline 
and/or ACh (Sarter and Parikh, 2005; Parikh and Sarter, 2006).  Supporting the possibility of 
choline, PNU-120596 was recently reported to enhance the effects of sub-threshold, physiological 
concentrations of choline on native α7 nAChR in hypothalamic neurons (Gusev and Uteshev, 
2010). 
      Our results are at odds with the recent study of Snoek et al., (2010) who reported that while 
AR-R17779 and GSK1345038A, two selective α7 nAChR agonists, reduced cytokine responses in 
vitro, they worsened the effects of DSS-induced colitis at low doses. The highest doses of these α7 
nAChR agonists ameliorated clinical parameters, without affecting colonic inflammation. Many 
factors could account for the differences between the two studies.  The route of administration 
does not seems to play a major role since the protective effects in the DSS model in our study was 
seen with α7 nAChR agonists after both systemic (via s.c. and i.p) and oral (via drinking water) 
routes of administration.  The efficacy at α7 nAChRs of the agonists used in the treatment is 
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another possible factor.  While no information on the pharmacological profile at nAChRs was 
available for GSK1345038A, AR-R17779 is a potent and selective partial (approximately 70% 
efficacy) α7 nAChR agonist (Papke et al., 2004). Both of our α7 nAChR agonists used are full α7 
nAChR agonists.  However, two major differences could have played an important role: the sex of 
the mice used and the disease severity. 
      In our study, we used male mice to investigate the role of α7 nAChRs in experimental colitis, 
while α7 nAChR agonists were tested in female mice in Snoek et al., (2010) report.  This is an 
important difference that could account for the lack of effects seen in the later study.  Indeed, sex 
differences to nicotine and nicotinic agonists in mice and rats were reported in pain (Craft and 
Milholland, 1998; Damaj, 2001) and dependence measures and behaviors (Isiegas et al., 2009; 
Lopez et al., 2003).  Finally, Snoek et al., (2010) used a relatively low concentration of DSS (1.5%) 
to induce experimental colitis in C57 female mice compared to 2.5% in male C57 mice used in our 
study.  The differences in severity of the disease may have affected susceptibility to DSS-induced 
lesions and modified the efficacy of α7 nAChR agonists. 
      The narrow window of anti-inflammatory effects of α7 nAChR agonists and PAM as shown 
by their U-shaped dose-effect curves in our results with the DSS test, was surprising.  While drug 
distribution and metabolism factors could account for such dose-response profile, the same 
phenomenon was seen with three structurally different α7 nAChR agonists.  This narrow window 
could have been related to the desensitization properties of α7 nAChRs agonists reported in vitro. 
However, a similar profile was observed with PNU-120596, a type II PAM known to cause a 
dramatic slowing of receptor desensitization (Bertrand and Gopalakrishnan, 2007).  Importantly, 
this narrow U-shaped dose-effect curve was not seen with α7 nAChRs agonists and PAMs in 
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animal models of cognition and pain (Rowley et al., 2010; Feuerbach et al., 2008; Timmermann et 
al., 2007).  Thus, making this phenomenon unique to the DSS experimental colitis in mice. 
       In conclusion, in the DSS colitis model, we found that α7 nAChR signaling may, at least in 
part play an important role in the protection against colitis development in mice. α7 nAChR 
agonists and PAM affected the clinical features of the DSS colitis disease and produced a U-
shaped dose-response curve.  Our results suggest that targeting α7 nAChRs is a viable therapeutic 
approach for intestinal inflammation diseases such as ulcerative colitis treatment. 
        Even though it has been established that α7 nAChR is an essential component of the vagus 
nerve activity in regulating cytokine production in the periphery (Tracey, 2007), nicotine can 
have multiple nAChR-stimulated pathways. It has been reported that nicotine can mediate its 
anti-inflammatory effect in immune cells such as macrophages through a non-α7 nicotinic 
receptors manner (Matsunaga et al., 2001), for example, van der Zanden et al., (2009) 
demonstrated that α4β2 nicotinic receptors mediate cholinergic anti-inflammatory effects in 
intestinal macrophages. Recently, it has been reported that α4β2 receptors partially mediated the 
nicotine anti-inflammatory effect through JAK2-STAT3 signaling pathway (Hosur and Loring, 
2011). 
6.4. Involvment of non-α7 nicotinic receptors in inflammation and experimental colitis 
model 
In our study, β2, and α5 nAChR subunits appear to not play a crucial role in the development 
and expression of colitis severity since there were no differences seen in either of the clinical 
parameters of disease activity score or the colon length in the β2, and α5 deficient mice and their 
littermates WT DSS-treated mice. However, Orr-Urtreger et al., (2005) reported the involvement 
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of α5, but not β4 nAChRs, in experimental colitis. In which, they reported that the percentage of 
mice body weight loss and the disease activity score after DSS treatment were higher in α5 KO 
but not β4 KO nAChRs mice.  The reason why α5 KO mice in their study displayed a 
pronounced effect in increasing the disease severity, shortening of the colon length, colonic 
MPO activity, and in histologyical damage score in DSS colitis model is unclear. The different 
adapted scoring systems for disease severity and histopathological damage from different 
experimental colitis models, may explain the varying observations. Here, we used similar DSS 
concentration, but possibly their α5 null mice background generation differ from our α5 KO 
mice. In addition, they did not report a mouse sex and strain they used in their study, since 
mouse strains have different susceptibility to DSS-inducd colitis model (Mahler et al., 1998).  
Moreover, their adapted disease activity index scoring system (Rachmilewitz et al., 2002) 
included only two clinical parameters, body weight loss and rectal bleeding; however, our 
combined score has four clinical features of colitis for disease activity index (Cooper et al., 
1993). In addition, their scoring system for the histology adapted from different model of colitis 
(Karmeli et al., 2000); however, we evaluated the total histological damage degree (Iba Y et al., 
2003) for more details see Chapter 2, materials and methods section.  Furthermore, in their study, 
nicotine reduced disease activity score in α5 null mice, but not in WT, noteworthy, they used 
similar dose and route of nicotine administration that we used and also has been reported to be 
effective in several experimental colitis models (Eliakim et al., 1998, 2001; Qiu et al., 1997; 
Ghia et al., 2006). Moreover, nicotine in their study did not reduce colonic MPO activity in the 
WT mice; however, Qiu et al. (1997) reported that oral nicotine (5-20 ug/ml) reduced MPO 
activity and colonic damage score. Similar observation reported by Ghia et al. (2006) after oral 
nicotine administration (20 ug/ml).  
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 In our study, α9 and α10 nicotinic receptor subtype seems to play a role in colitis severity and 
inflammation since chronic administration of α-RgIA, a α9α10 selective antagonist, at low dose 
of 0.02 mg/kg attenuated the clinical parameters in DSS colitis mice. However, this dose did not 
affect colonic inflammation including total histology damage score or colonic TNF-α levels. On 
the other hand, at high dose (0.2 mg/kg), α-conotoxin RgIA had neither effect on the colitis 
severity nor colonic TNF-α level. However, it significantly decreased the total colon histological 
damage score in a dose-dependant fashion. α-conotoxin RgIA at all tested doses (0.02, 0.1, 0.2 
mg/kg) was unable to reverse the shortening of the colon length of the DSS-treated mice.   DSS 
can cause colonic inflammation which may be due to the increase of the cholinergic cells number 
at the site of inflammation. It has been reported that α9α10 nicotinic acetylcholine receptor 
antagonists decreased the number of immune cells such as macrophages and lymphocytes, and 
positive choline acetyltransferase cells at the site of nerve injury (Vincler et al., 2006). RgIA may 
possibly act by a similar mechanism in the DSS-induced colitis model, that is, through 
antagonism of α9α10 nicotinic acetylcholine receptors on immune cells to reduce the 
inflammation development and disease activity. α-RgIA possibly mediate its anti-inflammatory 
effect through immune system  mechanisms; however, it not clear yet.  
6.5. Summary  
   In summary, we demonstrated that seven days of DSS treatment induces acute colitis in 
C57BL6 mice. Chronic oral administration of low doses of nicotine in the drinking water was 
protective in DSS-induced colitis in mice as shown in the clinical parameters, inflammation 
markers and histological features. However, modest effects were seen after intermittent s.c 
injection or continuous infusion of nicotine. Collectively, these results highlight that dose and 
route of administration play a critical role in the protective effect of nicotine in intestinal 
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inflammation.  Developing novel pharmaceutical formulation regimens such as topical nicotine 
administration to the colon (enema) could lead to decreased adverse effects seen with systemic 
nicotine use and ameliorate the clinical efficacy of nicotine in UC conditions.  Also, the lack of 
effect of cotinine suggests that this major metabolite does not mediate the anti-inflammatory 
effects of nicotine reported in rodents and human studies.   
In DSS colitis model, we found that the lack of α7 nAChR subtype is probably, at least in 
part a source of colitis development in α7 deficient mice. Our findings supported by using 
pharmacological evidence, where we found that selective α7 nAChR agonists PHA-543613 and 
choline reduced clinical parameters in DSS-treated mice and  inhibited the increase in the colonic 
TNF-α levels.  A similar profile was observed with of PNU-120596, a positive allosteric 
modulator for α7 nAChRs.  Our results showed that these α7 nAChR agonists were protective in 
the DSS model at a narrow dose range with a U-shaped dose-response curve.  
        For the non-α7 nAChRs; our results suggest that both β2 and α5 nAChR subunits do not 
seem to play a role in colitis severity. Importantly, our data demonstrated for the first time that  
α9 nAChR subtypes may play an important role in experimental colitis.  The α9 nAChR selective 
antagonist α-RgIA reduced the clinical parameters in the area under the curve of disease activity 
scores. Similarly to -α7 nAChRs agonists, a U-shaped dose-response curve was observed with α-
RgIA treatment.  
      To our knowledge, we are the first to report the importance of the dose and route of nicotine 
administration and the effect of cotinine, the α9α10 nicotinic acetylcholine receptor antagonist, 
and the positive allosteric modulator for α7 nAChR in the DSS-induced colitis model in mice.  
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6.6. Future Directions 
    This research opens up new avenues and strategy for experimental and clinical colitis research. 
Our data clearly showed that α7 nAChRs agonists and PAMs are good therapeutic candidates for 
treatment of colonic inflammation diseases such as UC.  Indeed, the current UC conventional 
therapy has poor efficacies and associated with undesirable adverse effects, or contraindicated in 
some UC patients. However, further research is needed to understand the underlyning 
mechanisms of the role of α7 nAChRs in colitis. For instance, nicotine has multiple targets, 
actions, and mechanisms to produce its anti-inflammatory effects.  Investigating the site of action 
of the anti-inflammatory effects of nicotine, α7 nAChRs agonists and PAMs can clarify the 
immune and non-immune targets of these drugs. For example, isolation of lamina propria and 
spleen mononuclear cells by gradient centrifugation or whole blood from C57BL/6 mice or 
peritoneal macrophages isolation from α7 WT/KO and measure some inflammatory mediators 
could add new insight whether their anti-inflammatory effect mediated systemically or  
perpherial in the immunce cells from colonic, or peritoneal cavity during DSS-induced colitis 
period. Notably, nicotine treatment reversed colitis severity in vagotomized mice (Ghia et al. 
2006, 2007). Although the vagus nerve innervates only the proximal two-thirds of the colon, 
some studies the involvement vagus nerve in experimental colitis based on the cholinergic anti-
inflammatory pathway concept in rodents. In fact, recent study by Vida et al., (2011), reported 
that systemic anti-inflammatory effect of the released acetylcholine of the celiac-mesenteric 
ganglia from vagus nerve activation is mediated through the α7 nAChR of the splenic nerve. de 
Jonge et al., (2005) demonstrated that macrophages inhibited after vagus nerve activation 
through Jak2-STAT3 signaling pathway activation. Thus, the idea that α7 nAChR mediated 
reduced inflammation through cholinergic vagus nerve activation and release of acetylcholine 
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seems to be indirect and more complicated.  The intracellular mechanisms that induce nicotinic 
inhibition of macrophage activation involve the activation of anti-inflammatory Jak2/Stat3/Socs3 
signaling pathways and inhibition of NF-κB signaling (Tracey, 2002; Gallowitsch-Puerta and 
Tracey, 2005; de Jonge et al., 2005; Arredondo et al., 2006). The effects of nicotine on NF-κB 
activity are significantly blocked by specific JAK2 inhibitor (AG-490) and STAT3 inhibitor 
(NSC74859) (Hosur and Loring, 2011). It would be of a great interest to utilize these selective 
inhibitors for JAK2 and/or STAT3 in vivo in DSS-treated mice and investigate the relevance of 
these pathways in the effects of α7 nAChR selective agonists to clarify some of the intracellular 
mechanisms.  
      The limited anatomical expression of α9α10 nAChRs might be an advantage in target these 
nicotinic receptor which also, could decrease the possibility of undesirable effects to occur 
especially the CNS side effects since the α9α10 subtype is neither express in brain nor in spinal 
cord.  Therefore, the availiabliliy of α9 KO mice and the new selective antagonist for these 
receptors could help to understand the role of α9α10 subtype in inflammation and colitis. 
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